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ABSTRACT 
 
 
Respiratory motion remains a significant challenge for radiation therapy in targeting 
the tumour.  The use of planning margins to avoid geometrical miss of the target 
volume during respiration results in excessive lung tissue irradiation that limits the 
prescribed dose to be safely delivered and escalated for better therapeutic gain.  The 
purpose of this study was to develop effective dose planning techniques for treatment 
to be performed under natural patient breathing.  The techniques accounted for the 
dosimetric influences of tumour movement and aimed to provide an optimized 
treatment volume by minimizing the internal target volume (ITV) without 
compromising the target coverage.   
 
In the study, the accumulated 4D dose distribution over the tumour volume was 
calculated using deformable image registration (DIR).  A DICOM-RT based 
tool-box was specially developed for automated 4D dose calculation and evaluations.  
A new concept of defining the internal target volume from 4D dose coverage, namely 
inverse ITV (iITV) was introduced via the dose volume enclosed by the minimum 
accumulated dose in the tumour during the respiratory cycle.  The dosimetric 
advantages of using this iITV with reference to the conventional ITV were confirmed 
in nine clinical cases by an average dose volume reduction of 16.4% (ranging from 
2.3% to 29.9%).  4D radiotherapy involves complex dose distribution which was 
found to be affected by a number of factors including tumour size, magnitude of 
tumour displacement, tumour motion characteristics and the reference phases 
selected for dose planning.  Our findings indicate that optimal dose planning was 
generally, but not always, achieved with the planning CT performed at the temporal 
mean tumour position and the degree of target coverage maximization strongly 
depends on the nature of tumour movement.  Moreover, the conventionally 
geometric defined treatment margin could over estimate the treatment volume for a 
required target coverage.   
  
In conclusion, 4D dose calculation based on DIR offers realistic dose estimation, as 
both geometric and temporal factors are considered, and also provides optimal dose 
plans by minimizing the treatment volume.  However, 4D radiation planning 
involves a number of factors resulting from the properties of tumours (eg. tumour 
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size, amplitude and characteristics of tumour motion, etc) and from the procedure of 
treatment planning (eg. reference phase for dose planning, penumbra of dose beam, 
employed treatment volume etc) that interactively affect the resultant dosimetry.  
Since these factors vary patient-by-patient, there is no single formula or universal 
solution that can be used to obtain optimal dose planning.  The 4D dose toolbox 
developed in this study could however provide a user friendly platform for 4D dose 
calculation and analysis, and allow the optimal treatment modalities and planning 
techniques to be determined for individuals.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Lung Cancer 
1.1.1 Overview of Lung Cancer 
Lung Cancer is the most common cancer in the world with 1.61 million new cases 
diagnosed every year.  In 2005 there were 172,570 new lung cases diagnosed in the 
United States, an estimated 94.7% of whom died as a result of their lung cancer.  
The UK cancer registry in 2008 also reported that lung cancer was the most common 
cause of death from cancer for both men and women, and was responsible for 
approximately 22% of all cancer deaths and 6% of all deaths in UK (Office for 
National Statistics 2008; ISD Online 2009; Northern Ireland Cancer Registry 2009).  
With a 5-year survival in the range 10-14%, lung cancer is the leading cause of 
cancer death and accounts for about 1 million deaths worldwide every year 
(Williams et al. 2001).  
 
Lung cancer is a disease caused by the rapid growth and division of cells that make 
up the lungs.  Under normal circumstances, lung cells reproduce in an orderly 
fashion to maintain tissue health and repair injuries.  However, when growth control 
is lost and cells divide too much and too fast a cellular mass (or tumour) is formed. If 
the mass is confined to a few cells layers and does not invade the surrounding tissues 
or organs, it is considered benign. However, if the mass spreads to adjacent tissues or 
organs, it is considered malignant or cancerous.  If the cancerous cells break away 
from the original tumour, travel and grow within other organs – such as the opposite 
lung, bone, brain, liver, adrenal glands, or lymph nodes of the chest, the process is 
known as metastasis. 
 
The risk factors for lung cancer include smoking, exposure to radon gas, industrial 
carcinogens and air pollution, family history and lifestyle (e.g., lack of physical 
activity, poor diet, excessive alcohol consumption). Tobacco smoking is the main 
aetiology causing approximately 90% of cases (Parkin 2011; Lubin et al. 2007; 
Lukanich 1999).  Passive smokers are also at increased risk of lung cancer (Doll et 
al. 1994; Janssen-Heijnen et al. 2003; Harkness et al. 2002; Taylor et al. 2001).  
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Radon
 
exposure
 
(Frumkin et al. 2001; Green et al. 2002; Darby et al. 2005) and 
certain occupational exposure to arsenic, asbestos, chromium, nickel and vinyl 
chloride also plays an important role in lung cancer (Armstrong et al. 2004; Richiardi 
et al. 2004). 
 
1.1.2 Types of Lung Cancer 
Lung cancer is classified into different types according to its histology and includes 
small cell carcinoma (SCLC), squamous cell carcinoma, adenocarcinoma, large cell 
carcinoma, broncho-alveolar carcinoma and undifferentiated pulmonary carcinoma.  
Squamous cell carcinoma and SCLC often are centrally located and may appear as 
pneumonia, atelectasis, or pit-like masses.  Adenocarcinoma and large cell 
carcinoma are usually found on the periphery of the lungs and may occur as solitary 
nodules.  Squamous cell cancers frequently are slow growing and can take several 
years to progress from a confined tumour into invasive cancer.  The prognosis of 
adenocarcinoma and large cell cancer tend to have a worse prognosis than squamous 
cell cancer at all stages.  
 
1.1.3 Causes of Lung Cancer 
Squamous cell carcinoma, adenocarcinoma and large cell carcinoma account for 
approximately 35%, 27% and 10% of all lung cancers, respectively (National 
Institute for Clinical Excellence. 2005), the remainder is SCLC.  The small cell 
carcinoma, squamous cell carcinoma and adenocarcinoma are the three principal 
histological types associated with smoking-related lung cancer.  Adenocarcinoma 
also account for the lung cancer in non-smokers.  In the United States, 
adenocarcinoma is now the most common type of lung cancer.  In Europe the most 
common type of lung cancer is still squamous cell carcinoma despite increases in the 
incidence of adenocarcinoma (Harkness et al. 2002).  The National Cancer Institute 
(NCI) also reported that adenocarcinoma is now more common than squamous cell 
carcinoma in both Caucasian and African American women.  In Hong Kong, there 
is very high rate of lung adenocarcinoma among Chinese women.  In addition, the 
rate of adenocarcinoma in Koreans is increasing in both sexes.  The causes for race- 
and sex-related differences in lung cancer histopathology are unknown.  Some 
experts suggest that adenocarcinoma in women may be increased by hormonal 
(endocrine) factors.  In particular, researchers believe that estrogen replacement 
  5 
therapy (ERT) increases the risk for adenocarcinoma (Riman et al. 2002).  Studies 
have also indicated that women may have a greater genetic susceptibility to specific 
types of lung cancer due to female, X-linked inheritance (inheritance of genes 
located on the X chromosome) (Hemminki et al 2005).  However, the increasing 
incidence of adenocarcinoma has been linked to low-tar cigarettes.    
 
Occupational exposure is also associated with certain histopathologic types of lung 
cancer.  For example, recent findings (Wild et al. 2000) suggest that long-term (20+ 
years) exposure to mineral and metal dust is related to the growth of both small cell 
and squamous cell carcinomas.  In addition, asbestos exposure may be associated 
with the development of adenocarcinoma and, to a lesser degree, with squamous cell 
or anaplastic carcinoma (cancer in which the cells have lost specialized 
characteristics, including physical placement).  Some investigators theorize that 
household exposure to low-dose radon over long period of time may increase the risk 
of small cell lung carcinoma (Alavanja et al. 1999). 
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1.2 Conventional Treatment Methods for Lung Cancer 
There are three options for treating the primary lung cancer namely surgery, 
chemotherapy and radiation therapy and these may be applied alone or in 
combination.  The choice of treatments depends on a number of factors, including 
the histological type, the stage of the disease and the physical condition of the 
patient. 
 
For treatment considerations, lung cancer is divided into two groups: Small Cell 
Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC).  The 
NSCLC which include squamous cell carcinoma, adenocarcinoma and large cell 
carcinoma accounts for 80-85% of all lung cancers (National Institute for Clinical 
Excellence. 2005).  There are substantial differences between NSCLC and SCLC in 
both treatment and prognosis.  In general, SCLC tends to be more aggressive and 
spread sooner to distant sites.  Studies suggest that 60-70% of patients with SCLC 
show evidence of distance spread at the time of initial diagnosis.  Treatment of 
SCLC is not based upon surgery.  In fact SCLC is considered to be more responsive 
to the systematic treatment approach such as chemotherapy and radiotherapy.  In 
contrast, NSCLC may not have spread at the time of diagnosis and surgical resection 
of the tumour is the treatment of choice. 
 
The TNM classification for staging of lung cancer was revised in 1997 (Mountain 
1997) (Table 1.0).  The stage of the disease is classified according to the size, 
location of the tumour and whether the cancer has spread to or beyond the lymph 
nodes.  For the early stage NSCLC with no lymph node involvement, surgical 
resection of the tumour is the principal form of treatment for the patient.  If patients 
are unable to undergo tumour resection, radiotherapy is considered with the aim of 
eradicating the primary tumour.  For the advance stage disease where obvious 
lymph nodes or/and metastases are involved, a combination treatment involving 
radiation therapy and chemotherapy is applied.  However, it is unclear whether or 
not disease-free or overall survival is improved when surgery is performed after 
concurrent combination therapy.  
 
Table 1.0  TMN classification for lung cancer 
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0 Carcinoma in situ 
IA T1N0MO 
IB T2N0M0 
IIA T1N1M0 
IIB T2N1M0, T3N0M0 
IIIA T3N1M0, T1—T3N2M0 
IIIB T4N0—N3M0, T1—T3N3M0 
IV any T any N M1 
TX Primary tumour cannot be assessed, or tumour proven by the 
presence of malignant cells in sputum or bronchial washings but 
not visualized by imaging or bronchoscopy 
T0 No evidence of tumour 
T1 Tumour </3 cm in greatest dimension, surrounded by lung or 
visceral pleura, without bronchoscopic evidence of invasion more 
T2 Tumour with any of the following features of size or extent: >3 cm, 
involves main bronchus >2 cm distal to carina, invades the visceral 
pleura. Associated with atelectasis or obstructive pneumonitis that 
extends to the hilar region but does not involve the entire lung.  
T3 Tumour of any size that directly invades any of the following: chest 
wall (including superior sulcus tumours), diaphragm, mediastinal 
pleura, parietal pericardium; or tumour in the main bronchus </2 
cm distal to carina, but without involvement of the carina; or 
associated atelectasis or obstructive pneumonitis of the entire lung 
T4 Tumour of any size that invades any of the following: mediastinum, 
heart, great vessels, trachea, oesophagus, vertebral body, carina; or 
tumour with a malignant pleural or pericardial effusion, or with 
satellite tumour nodule(s) within the ipsilateral primary tumour 
lobe of the lung 
Nx Regional lymph nodes cannot be assessed 
N0 No evidence of lymph node 
N1 Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph 
nodes and intrapulmonary nodes involved by direct extension of 
the primary tumour 
N2 Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis to contralateral mediastinal, contralateral hilar, 
ipsilateral or contralateral scalene, or supraclavicular lymph node(s) 
Mx Pr  Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
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1.3  Enhanced Radiation Treatment for Lung Cancer – Stereotactic 
Hypo-fractionated Radiation Therapy  
The most common types of lung cancer affecting 75%-80% of patients are grouped 
under NSCLC (Michaiski, et al. 2004).  Of these, approximately 15-20% present 
with early or localized disease, with the primary tumour in the lung and no nodule 
involvement, or metastases elsewhere.  With increasing use of Computed 
Tomography (CT) for staging cases of secondary lung cancer, the number of patients 
with the disease is expected to rise significantly in the coming decades. 
 
Surgery is the main curative treatment for the early stage NSCLC patients and is 
generally accepted as the treatment of choice.  Five-year survival rates for early 
stage patient treated with radical surgery, specially a lobectomy or pneumonectomy, 
are over 60% (Mountain 1997; Naruke et al 1988)  and as high as 80% for very 
early squamous cells carcinoma (Souhami et al. 2005).  The local control rate was 
reported to be over 90% (Martini et al. 1995).  However, some patients are not 
suitable surgical candidates for a number of reasons including poor pulmonary 
reserve, cardiac dysfunctions, vascular disease, diabetes mellitus, general frailty or 
other co-morbidities.  In the case of poor pulmonary reserve, extensive surgical 
resection is restricted especially for patients with centrally located tumours.  
Moreover, many of the co-morbidities impact on the anaesthetic and peri-operative 
risk, and thus preclude any surgical procedure.  These patients are typically 
considered for radiation therapy, with the aim of eradicating the primary tumour.    
 
1.3.1 Treatment Rationale 
Conventional radiation therapy, however, has inferior results when compared to 
surgical series; with local control of 56% and 5-year survival rates ranging from 10% 
to 30% (Haffty et al. 1998; Dosoretz et al. 1992; Morita et al. 1997).  The poor 
outcomes are partly accounted for by the lower rate of tumour eradication and the 
selection of less fit patient.  Conventional radiotherapy typically consists of 50-66 
Gy total dose in 1.8-2.5 Gy per fraction, that is equivalent to Biological Effective 
Dose 10Gy (BED10) ranging from 64.9 – 68.8 Gy. Some studies, however, 
demonstrate a benefit to local control by dose escalation.  Blomgren and Lax 
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(Blomgren et al. 1998) developed stereotactic radiotherapy for early stage NSCLC 
and demonstrated that dose escalation was associated with better local control and 
survival than conventional radiation therapy.  The relationship between dose 
escalation and local control was further demonstrated by Onishi et al (2004), 
McGarry et al (2005) and Wulf et al (2005).  Onishi et al showed a lower cancer 
recurrence rate with BED10 ≧ 100Gy compared to BED10 ≦ 100Gy (8.1% vs 26.4%, 
p=0.04) for stage 1 NSCLC using stereotactic radiotherapy.  Wulf et al reported a 
steep dose-response curve using BED10.  Encouraging treatment results on 
hypofractionation stereotactic radiotherapy for stage 1 NSCLC have been reported in 
numerous studies.  Ng et al (2008) treated patients with dose escalation of BED10 
ranged from 90 to 151 and reported 2-year local control and cancer specific survival 
(CSS) rates of 94.7% and 77.6%, which are very close to those obtained by 
Fukumoto et al (2002) of 94% and 73%, respectively.  Hoyer et al (2006) also 
reported a 62% 2-year CSS.  Onishi et al (2004)
 
reported both 3- and 5-year CSS of 
78%.  Five-year overall survival had been reported to be 30% -83%, significantly 
higher than the figure of 15% obtained when patients are treated with conventional 
radiotherapy.  This suggests that medically unfit patients would still benefit from 
the enhanced radiation treatment technique.  
 
The rationale of stereotactic hypo-fractionated radiation therapy (SHRT) is based on 
the principles and experience gained from stereotactic brain radiosurgery that allows 
delivery of very high doses of radiation confined to the tumour region, usually in 
several large fractions (hypofractionated), by multiple co-planar and non-coplanar 
beam guided by a set of stereotactic coordinates system.  SHRT requires a precise 
definition of the target, assessment and management of target motion, determination 
of an effective planning target volume according to the accuracy of target 
localization of individual centre, conformal RT planning and daily quality assurance 
on treatment setup.  SHRT was developed in the early 1990s in the Karolinska 
Institute in Stockholm, Sweden (Blomgren et al. 1995), and has been used as an 
accepted alternative treatment for patients with early stage lung cancer in many 
centres in Japan and Germany, U.S.A. and elsewhere.  Large fraction size is 
essential for effective outcomes of SHRT as it dominates the BED.  A number of 
fractionation schedules have been employed, including single fractions of 20Gy 
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-26Gy and various fractionated regimens (commonly 3 to 5 fractions).   
 
1.3.2 Implementation Requirements 
In addition to the various dose-fractionation schemes, the technical aspects of 
treatment planning and treatment delivery to make the SHRT more effective are also 
important as these technical factors clearly influence the dose delivery to the tumour 
and the organs at risk, and thus, may impact on both local control and the 
radiation-induced toxicity.  A major challenge for implementing the SHRT for 
patients with lung cancer is the tumour motion caused by breathing.  Some studies 
have reported that up to 40% of lung tumours move by more than 5 mm and of these 
10-12% move by more than 1 cm (Liu et al. 2007; Donnelly et al. 2007).   However, 
conventional treatment planning techniques based on CT images performed on free 
breathing carry no information of tumour movement.  To avoid geometrical misses 
of the target, it is necessary to apply safety margins which are substantially extended 
beyond the gross tumour volume to create the planning target volume (PTV).  This 
results in excessive lung tissue irradiation and restricts the ability of dose escalation.  
To mitigate the effect of motion, many treatment methods have been proposed or in 
current clinical usage (Ohara et al. 1989; Minohara et al. 2000; Kubo et al. 1996; 
Keall et al. 2001; Mageras G.S 2001).  The effect of tumour motion on radiotherapy 
planning and the different approaches adopted by various researchers to mitigate this 
are reviewed in the following chapters.  
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1.4 Treatment Techniques for Stereotactic Hypo-fractionated Radiation 
Therapy 
To address the issue of tumour motion, several sophisticated treatment delivery 
methods such as respiratory gating, tracking of tumour motion or tumour 
immobilization using breath-hold have been developed, in an attempt to reduce the 
treatment margin required and hence allow dose escalation and consequently 
minimize toxicity caused by the excessive irradiation of healthy tissue (Barnes et al. 
2003; Wong et al. 1999; Engelsman et al. 2005; Mageras et al. 2004; Berbeco 2005; 
Brown et al. 2007).  
 
In respiratory gating, surrogates of tumour motion are used to trigger the therapeutic 
beam.  Shirato et al (2000) have established a method for gating the respiratory 
movement based on the three-dimensional location of a fiducial implanted near the 
tumour.  Continuous multi-view of the fiducial is employed to ensure that the 
radiation is being delivered accurately.  Schweikard et al (2000)
 
used infrared 
external markers and implanted radio-opaque markers to periodically reestablish the 
correlation between internal and external movement throughout an irradiation session 
using the Cyberknife system (Accuray, Inc, Sunnyvale, CA, USA).  Many institutes 
have also developed techniques for respiratory gating based on the position of an 
external surrogate placed on the thorax or abdomen, or with occasional verification 
of internal anatomy using x-ray if available.  In such cases, the desired treatment 
outcomes are therefore strongly dependent on patients having a repeatable or 
predictable respiratory pattern; otherwise the results could be adversely affected.  
However, geometric uncertainty resulting from the poor correlation between internal 
tumour motion and movement of external surrogates has been the major pitfall for 
the respiratory gated radiotherapy (RGRT) (Li et al. 2007; Berbeco et al. 2005). 
RGRT also requires longer treatment delivery time as irradiation only proceed at the 
respiratory ‘gate’ (20%-30% of the respiratory cycle), which can in turn increase the 
risk of patient movement during treatment (Korreman et al. 2008).  Muirhead et al 
(2010) evaluated the potential clinical benefit of RGRT in lung cancer and showed 
that the reduction in toxicity parameter was limited in comparison with non-gated 
(continuous) 4DCT irradiation due to the intrinsic errors involved in RGRT.   
 
On the other hand, instead of tracing tumour motion, tumour immobilization during 
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irradiation was pioneered by Wong et al (1999)
 
using spirometry.  The tumour is 
temporarily immobilized under deep inspiration breath hold using the active 
breathing control system (ABC). The deep inspiration breath hold (DIBH) technique 
has the potential benefits of better tumour immobilization and since this maximizes 
lung capacity, toxicity is minimized thus allowing treatment with potential dose 
escalation.  However, with such a technique, training must be provided prior to 
treatment and this may not be tolerated by all patients.  Unstable breathhold control 
could induce unsatisfactory target immobilization thereby resulting in possible 
treatment failure.  With these techniques, compliance of the patients to ensure a 
reproducible breathing pattern is a pre-requisite in achieving a desirable outcome 
with the enhanced treatment.  
 
The most consistent and stable tumour movement is expected with natural breathing 
of the patient.  Therefore, despite the availability of the advanced delivery 
techniques, recent studies have re-employed a free-breathing treatment technique 
with the treatment margin carefully determined to account for the tumour motion.  
The concept of internal target volume (ITV) has been suggested by the International 
Commission on Radiation Units and Measurements (ICRU) report 62 (1999).  The 
ITV is defined as the clinical target volume (CTV) plus an additional margin to 
account for geometric uncertainties due to internal variations in tumour position, size 
and shape.  The CTV cannot be visualized with the current imaging modalities.  
The ITV is defined by delineation of the gross tumour volume (GTV) on each of the 
phases that constitute the four-dimensional computed tomography (4D-CT) image 
date set, followed by expansion of each GTV to account for the microscopic spread 
of disease.  To make the determination of the ITV more applicable, a recent study 
(Ezhil et al. 2009) modified the determination of ITV by proposing the concept of 
internal gross tumour volume (IGTV) which explicitly accounts for internal 
variations in tumour position, size and shape but is directly derived from imaging 
studies.  The ITV was then determined to be the IGTV plus a margin that accounts 
for microscopic disease.  IGTV is therefore generated by contouring the GTV on 
each binned phase (typically ten) of the 4D-CT dataset.  The merging of these 
individual three-dimensional (3D) volumes into a single 3D volume represents the 
IGTV, which denotes the volume of the entire moving tumour.  To speed up the 
contouring process, the IGTV can be generated directly on the maximum intensity 
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projection (MIP) image data set, in which each voxel represents the maximum 
intensity encountered by corresponding voxels in all individual 3D data sets of the 
4D-CT.  This avoids the need to perform contouring the tumour volume on every 
data set.    The post processing of MIP images has been commonly applied for 
defining the ITV for clinical applications.  Another alternative to determining the 
IGTV by using breath-hold CT imaging is to acquire images at the two extremes (end 
expiration; end inspiration) of the respiratory cycle.  The GTV of each phase is then 
contoured and the GTVs are then combined to form the IGTV.  However, both 
alternated methods were found to be sub-optimal for IGTV determination.  The 
poor visibility of the MIP images and the possible tumour deformation between the 
two extreme phases of the breathing and the curved motion pathway during breathing 
may introduce uncertainty.  To identify the most effective delineating technique, 
studies (Ezhil et al 2009; Underberg et al. 2005; Bradley et al. 2006; Cai et al. 2007) 
have been carried out to evaluate the delineation accuracy of IGTV using the 
ten-phase IGTV as reference.   
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1.5  Aims and Objectives of the Thesis 
The concept of ITV and IGTV accounts for the tumour motion only from the 
geometrical aspect but does not take into consideration the temporal movement of 
the tumour which may lead to excessive irradiation being delivered to the 
neighbouring healthy tissue.  For instance, tumour coverage shown on each phase 
of the respiratory cycle occurs during only a fraction of the time, but according to the 
definition of ITV/IGTV, radiation dose is assigned over the whole breathing cycle.   
A more appropriate ITV would achieve optimal dose coverage by accounting for the 
dynamic tumour motion.  Several studies (Ezhil et al. 2009; Germain et al. 2008; 
Kang et al. 2007) have proposed a 4D-dose calculation based on the convolution of 
the static dose distribution with the probability distribution function (PDF) of the 
organ motion.  Such an approach only accounts for translational displacement and 
the influence of non-rigid anatomical displacement (i.e. deformable anatomical 
change) on the dose distribution during breathing is not considered.   
 
This thesis is concerned with radiotherapy treatment planning in the presence of 
significant tumour movement and aims to investigate and develop an optimal 
treatment planning technique for lung cancer where the treatment is carried out with 
natural breathing of the patients.  The study is based on the realistic treatment doses 
over the moving tumour which is evaluated in 4D accounting for both spatial and 
temporal factors.  
 
In this work, the 4D dose distribution over the moving target was calculated using 
deformable image registration (DIR), which explicitly takes into account the 
anatomical changes in shape, volume, position and density during respiration.  The 
DIR tracks the displacement of each voxel of the CT image during the respiratory 
cycle.  Summation of the dose along the trajectory of each voxel generates a 
realistic 4D dose.  Since the 4D dose calculation is complex and involves 
considerable quantities of dose data, a DICOM-RT based tool box was devised as 
part of this study in order to automate the dose calculation.  The tool box literally 
transforms any DICOM-RT dose plan from 3D to 4D based on deformable 
voxel-dose registration.  Using the tool box, the 4D dose distribution over the target 
volume was retrospectively evaluated in nine clinical cases.  The several aspects 
which are involved in realizing the optimal 4D dose planning for treatment of lung 
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cancer were explored.  The main pertinent topics are briefly introduced below.  
 
1) By converting the 3D spatial dose distribution to the 4D spatial-temporal dose 
distribution, the actual accumulated dose received by the tumour can be revealed.  
In determining the 4D dose distribution over the tumour, a new concept of 
defining the internal target volume from 4D dosimetry is proposed.  The inverse 
ITV (iITV ) is introduced in this study.  [discussed in Chapter 5, section 2] 
 
2) The planning target volume is considered to be the crucial factor for maximizing 
the therapeutic ratio, as it affects the degree of radiation induced toxicity and 
hence the potential for dose escalation.  Minimizing the internal treatment 
volume is one of the pathways to achieve the goal.  Whether this can be fulfilled 
by the proposed iITV without compromising the target coverage is one of the 
concerns which was assessed in the study. [discussed in Chapter 5, section 3,  
Chapter 5, section 4]. 
 
3) In general, the under dosage of an irradiated target is considered to be highly 
associated with the magnitude of tumour movement.  This is conventionally 
compensated by an additional treatment margin with magnitude directly related 
to the range of tumour movement.  This leads to a substantial irradiated lung 
volume and the opportunity for increasing prescribed dose is limited.  There 
also remains a controversy (Murphy et al. 2007; Spoelstra et al. 2008.) 
concerning the threshold of tumour motion where respiratory management of 
tumour movement should be considered during treatment.  Considering that the 
influence on dose distribution with the same magnitude of movement is far more 
significant for a small sized target than a large one, then there is a question mark 
about whether the ITV margin should be applied regardless the target size.  
Consequently this leads to the question as to how the treatment techniques should 
be determined for individual cases.  The tumour characteristic which may 
significantly affect the treatment dose are investigated with the aim of identifying 
the important factors for the optimal treatment planning.  [discussed in Chapter 
6] 
 
4) In reviewing the numerous studies of lung cancer radiotherapy, the deep 
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inspiration breath hold technique appears to have potential benefits of better 
tumour immobility and minimized toxicity due to maximized lung capacity.  
However, such technique may be poorly tolerated by patients with compromised 
pulmonary function.  The effectiveness of treatment techniques between the 4D 
treatment planning with free breathing (proposed in this study) and 3D treatment  
planning with deep inspiration breath hold is compared for optimized dosimetry 
for selected cases.  The most effective and suitable treatment technique for 
individual patients is determined upon the projected treatment outcomes.  
[discussed in Chapters 7 and 8] 
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 CHAPTER 2 
 
DICOM-RT BASED TOOL BOX FOR FOUR DIMENSIONAL NON-RIGID 
DOSE CALCULATION 
 
2.1 Design of DICOM-RT Based Tool box  
A toolbox that consists of five main functions was developed for this study.  This 
was written in the MATLAB (Version 7.6, R2008a, The Mathworks Inc.) scientific 
software environment, in conjunction with CERR, an open source computational 
environment for radiotherapy research for DICOM images and DICOM-RT data 
access and analysis.  The 4D dose calculation was performed using Image 
Morphing (IM) (BrainLab, White paper), a deformable image registration tool 
provided by BrainLab Ltd (Germany).  This allows the displacement of each voxel 
to be tracked during a respiratory cycle and consequently the accumulated dose along 
the trajectory of each voxel to be generated.   
 
A) Treatment Planning Data Import 
A full set of 4D CT images and the dose plans in DICOM-RT format were imported 
into the computation environment for Radiotherapy Research software (CERR) 
where the dose value and its corresponding position were contained in a 3D array.  
The positions of the dose points in the transverse plane were defined according to the 
CT pixels in a 512 x 512 matrix (Figure 2.1).  The position along the cranio-caudal 
direction was indicated by the CT slice number.  For example A (1, 2, 1) indicates 
dose point located at the 1
st
 row, 2
nd
 column and 1
st
 CT slice.  The spatial dose 
resolution (grid interval) defined by the pixel size and the size of the scanning field 
(520 mm was employed in the study ) was 1.01 mm in the lateral and the 
anterior-posterior directions and 3 mm in the caudal- cranial direction as determined 
by the CT slice thickness.   
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Figure 2.1 The dose points presented in 3D array with CERR  
 
 
B) Deformable Image Registration – Image Morphing 
To identify the displacement trajectory of each voxel during breathing, the 
deformable image registration tools, Image Morphing (IM) provided by the iPlan 
(BrainLab Ltd) treatment planning system was used.  IM employs a 
knowledge-based segmentation approach (Chao, Schreibmann, et al. 2006) in which 
the anatomical structures are morphed from the source images to the target images by 
comparing the image data.  The source data is deformed based on similarity 
calculation using mutual information and cross correlation algorithm to improve the 
similarities in voxel density until a match is found.  Once the similarity measure is 
defined, the registration algorithm optimizes the similarities by adjusting the 
transformation vectors in an iterative process.  When the point-to-point 
correspondence of the two datasets is identified, the software automatically transfers 
all outlined structures of the source onto the target data set.  As a result, the 
deformation vector field, which defines a unique mapping from the source onto the 
target data set, is generated.  Figure 2.2 illustrates the morphing process; IM creates 
a virtual grid of points in the source data set and matches them with a grid of points 
on the target data set.  Since each grid point is indexed and its location is recorded 
in 3D co-ordinates, the voxel displacement caused by breathing can be traced by the 
position of the corresponding grid point.  The output file generated by IM is 
formatted into a 6D array with the 3D CT co-ordinates of the corresponding grid 
point for the source data set and the target data set recorded in the 1
st
 – 3rd 
components and 4
th
 - 6
th
 components of the array, respectively.  For example, M 
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denotes the morph array, and M (1) = [1, 2, 3, 4, 5, 6] implies that the first voxel with 
the CT coordinates of (1, 2, 3) in the source image was displaced to the CT 
coordinates of (4, 5, 6) in the target image (figure 2.2).  The 3D spatial resolution of 
the grid point was 1 mm.  A sample of M matrix is shown in Table 2.1.  
  20 
Figure 2.2 Deformable image registration using Image Morphing (IM). Voxels with CT coordinates (x, y, z) in the source image displaced to (x’, 
y’, z’) in the target image was depicted by the morph matrix “M” 
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Table 2.1 An example of M matrix containing geometric data of GTV at inhale phase 
(source) and exhale phase (target) is shown in the table below.  
 
Source data (mm) Target data (mm) 
x1 y1 z1 x1’ y1’ z1’ 
63 -125 -307 62 -123 -306 
64 -125 -307 63 -123 -306 
65 -125 -307 64 -123 -306 
66 -125 -307 65 -123 -306 
67 -125 -307 66 -123 -306 
68 -125 -307 67 -123 -306 
69 -125 -307 68 -123 -306 
70 -125 -307 69 -122 -306 
71 -125 -307 70 -122 -306 
72 -125 -307 71 -122 -306 
73 -125 -307 72 -122 -306 
74 -125 -307 74 -122 -306 
75 -125 -307 75 -122 -305 
76 -125 -307 76 -122 -305 
77 -125 -307 77 -121 -305 
78 -125 -307 78 -121 -305 
79 -125 -307 79 -121 -306 
80 -125 -307 80 -122 -306 
81 -125 -307 81 -122 -306 
82 -125 -307 82 -122 -306 
83 -125 -307 83 -122 -306 
84 -125 -307 84 -122 -306 
85 -125 -307 85 -122 -306 
86 -125 -307 86 -123 -307 
87 -125 -307 87 -123 -306 
63 -125 -307 62 -122 -306 
64 -125 -307 63 -122 -306 
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C) DE-DOSE-REG function  
The function of DE-DOSE-REG is to register each voxel of the reference CT with 
the temporal dose received by the corresponding voxel of each individual 4D-CT sets.  
The corresponding voxels were acquired with the morphed vectors contained in the n 
x m matrix (M) generated by IM, where n denotes the number of voxels and m their 
coordinates.  The configuration of M is described in figure 2.2.  In accordance 
with the displaced position of the voxel, the temporal dose at each voxel was traced 
with the 3D dose array (figure 2.1) obtained from the individual 4D-CT plans.  In 
order to match the positioning format between the 3D dose array and M, the 3D dose 
array containing dose points in grid order was converted into 3D CT coordinates.  
Moreover, the spatial dose resolution along the cranio-caudal direction which was 
defined by the slice thickness was refined from 3 mm to 1 mm by linear interpolation 
between point doses.  The temporal doses at each bin of a phase-sorted 4D CT 
images were finally stored in a 1D dose array, namely TDx (where x denotes the 
phase bin; the percentile of the period of the corresponding breathing cycle of the 
patient), in the order of voxels presented in M1-n, 1-3.  The procedures for 
determining the DE-DOSE-REG function is illustrated in figure 2.3. The Program 
code of DE_DOSE_REG is listed in Appendix I.1  
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Figure 2.3 Combining the information of dose point (in 3D dose array) with the 
morphed data (in M matrix) for 4D dose calculation.   
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D) AUTO-CERR-DOSE function 
This function permits the temporal dose received by each voxel at each respiratory 
phase to be revealed visually on the reference CT.  This was done by replacing the 
3D dose array of the reference plan with TDx,, and superimposing the new doses on 
the reference CT.   
 
E) ADD-ALL-DOSE function 
This function derives the complete 4D dose distribution over the entire respiratory 
cycle by the time-weighted dose summation of TDx for all phases (figure 2.4).  
Together with the function AUTO-CERR-DOSE, the resultant 4D dose was 
displayed and assessed geometrically under the CERR environment.  A sample of 
TDx is shown in Table 2.2. The complete process of 4D dose calculation using the 
tool-box is illustrated in Figure 2.5.  The Program code of ADD-ALL-DOSE is listed 
in Appendix I.2  
 
 
 
Figure 2.4 The accumulated dose distribution over the entire respiratory cycle was 
obtained by time-weighted dose summation of TDx for all phases. TD’X% denotes the 
amount of tumour doses received only at the x% breathing phase by multiplying a 
time weighting factor to the TDx.  
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Table 2.2 An example of TDx. Data extracted from a clinical case (case 3 of the study).  Due to the dramatic movement between phase 0% to 
10% and phase 60% to 80% (see figure 6.2 for the tumour movement trajectory), the temporal doses at the corresponding voxels are substantially 
changed. TDall is the time-weighted dose summation of all TDx 
Voxel 
No 
Voxel Dose (Gy) 
TD_0 TD_10 TD_20 TD_30 TD_40 TD_50 TD_60 TD_70 TD_80 TD_90 TD_all 
12527 21.1677 13.1066 3.9216 3.918 3.9204 2.8987 3.9102 3.9456 13.0703 17.8279 8.7687 
12528 19.4044 12.9931 8.3529 3.854 3.8546 3.8489 3.8481 3.8875 12.9597 17.724 9.0727 
12529 19.1791 12.7968 8.1961 3.7687 3.7726 3.7629 3.7633 3.8051 12.7401 17.4975 8.9282 
12530 18.5239 12.3833 8.0191 7.8786 3.6582 3.6475 3.6472 7.9947 12.3249 17.0427 9.512 
12531 17.8468 11.8509 7.6904 3.5223 3.5276 3.5197 3.5193 7.6704 11.7943 16.2773 8.7219 
12532 16.9972 11.2713 7.3301 3.3701 3.4305 3.3683 7.1736 7.3145 11.2249 15.5369 8.7017 
12533 16.5485 10.9668 7.1402 7.0068 7.1489 6.9904 6.9934 7.1238 10.9229 14.7961 9.5638 
12534 16.0998 10.6623 10.4358 6.8291 10.4521 6.934 6.9328 10.6041 10.6208 14.3779 10.3949 
12535 15.2867 9.5647 10.0962 9.919 9.9349 6.5787 6.2235 10.0624 10.0795 13.6505 10.1396 
12536 9.4979 9.4911 7.1066 7.0948 4.8016 4.1729 4.1749 4.7957 7.1343 6.6594 6.4929 
12537 10.0152 6.7408 7.4832 4.8048 5.0351 4.523 4.5227 5.03 7.5095 7.3436 6.3008 
12538 10.5325 7.0615 4.9525 5.2746 5.2686 4.7252 4.7249 5.2643 7.8847 7.7462 6.3435 
12539 11.6855 7.3823 5.42 5.4086 5.7927 2.5765 2.5773 5.7803 8.7126 8.1489 6.3485 
12540 13.0737 8.7483 5.9463 5.9309 5.9273 2.7742 2.7753 5.9206 9.715 12.0468 7.2858 
12541 14.4982 9.7544 6.5625 6.5509 6.5479 2.9843 2.9866 6.5363 10.7331 14.4691 8.1623 
12542 17.744 10.7693 7.2186 7.2074 7.2042 3.2037 3.2063 7.1907 11.7623 15.9279 9.1434 
12543 18.5438 11.8023 7.7377 7.7199 7.718 3.4113 3.4109 7.6983 12.4338 16.8632 9.7339 
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Figure 2.5 A flow-chart for 4D dose calculation using the tool-box 
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2.2 Evaluation of Deformable Image Registration of IM 
The performance of image morphing using IM was evaluated by calculating the 
Matching Index (Lin, Shi., et al. (2008).  The Matching Index is defined as the ratio 
of the intersected volume between the morphed contour and the manual contour to 
the union of the two volumes.  Using CT lung window, the GTV was manually 
delineated and the lung volume using auto-segmentation (iPlan) with manual 
correction where necessary.  The contours were initially delineated on the planning 
CT selected at end-inhale (PLCTin) as the source contours and were morphed onto 
the planning CT selected at end-exhale (PLCTex) defining the morph_contour which 
was then compared with the contours manually delineated on the PLCTex.  The 
contouring was performed by a physicist, and confirmed by an oncologist if any 
uncertainty was found.  
 
Matching Index = 
contourmanualcontourmorph
contourmanualcontourmorph
__
__


 
 
The matching indices between the manual_contour and the morph_contour of lung 
volume and of the GTV for all cases were found to be between 0.93 and 0.98 (mean 
= 0.95 ± 0.01) and between 0.74 and 0.98 (mean = 0.84 ± 0.08), respectively.  
The index values are listed in table 2.3. The matching indices for lung mapping were 
comparable with those (range: 0.94 – 0.95) reported in Lin et al’s (2008) study.  
The lower matching index for the GTV may be due to the limitation of image spatial 
and contrast resolution which would affect manual contouring particularly when the 
tumour volume is small. 
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Table 2.3  Matching indices between the manual_contour and the morph_contour of 
lung volume and of the GTV for all cases 
 Matching Indices 
manual_contour (PLCTex)  vs  morph_contour (PLCTin → PLCTex) 
GTV Lung 
1 0.79 0.95 
2 0.81 0.98 
3 0.74 0.96 
4 0.94 0.93 
5 0.75 0.95 
6 0.94 0.93 
7 0.90 0.95 
8 0.84 0.96 
9 0.98 0.96 
Mean ± std  0.84 ± 0.08 0.95 ± 0.01 
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CHAPTER 3 
 
RETROSPECTIVE CLINICAL STUDY ON 4D DOSIMETRY 
 
3.1   Clinical Background 
Hypofractionated stereotactic radiotherapy has been used to treat lung cancer at the 
Tuen Mun Hospital in Hong Kong since 2000.  Due to the roll out of the radiation 
delivery systems at the stage of treatment, several treatment techniques with different 
delivery modalities were developed and applied.  Over the period 2000 - 2010, 49 
patients with early stage NSCLC were prescribed with doses ranging from 45 to54 
Gy with 1 – 2 fractions per week for a total of 3-4 fractions.  The treatment 
planning technique was modified according to the delivery techniques and was 
described as following.  Cases meeting the research criteria were selected for the 
study.  
 
3.1.1 Patients Selection 
Patients attending a local tertiary oncology centre in Hong Kong who were 
pathologically proven to have NSCLC according to the WHO criteria were included 
in this study.  Stage I disease as defined by the guidelines given by The American 
Joint Committee on Cancer (AJCC) was confirmed by CT of the thorax and upper 
abdomen in all cases.  All the patients were considered medically inoperable or had 
refused surgery after assessment by a physician or thoracic surgeon.  
 
3.1.2 Radiotherapy Planning and Treatment Techniques Applied in Chronological 
Order 
From 2000-2003, patients were simulated and treated with shallow free breathing.  
The internal margin was estimated according to the CT simulation images by a 
radiation oncologist who is a specialist in this field.  Margins in the range of 1 to 2 
cm were added to the GTV depending on the magnitude of tumour movement.  
These encompass the microscopic extent of the tumour beyond the visible GTV, 
tumour motion as well as the setup uncertainty to form the PTV.   
 
From 2004, all the selected patients underwent fluoroscopic screening.  If tumour 
movement was greater than 1 cm in cranio-caudal, anterio-posterior or lateral 
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directions, or with tumour located near to the rib cage (< 2cm), the patient was 
selected for treatment with the deep inspiration breath-hold technique using active 
breath control (ABC) system developed by Wong et al (1999).  For patients who 
could not comply with the ABC system, treatment was performed under free 
breathing.  For patients treated with free breathing after 2004, two sets of 
conventional CT images were obtained during inspiration and expiration guided by 
the real-time position management system (RPM, Varian).  The GTV was 
delineated using a lung CT window (1000, - 500 Hounsfield units).  The IGTV was 
generated from the sum of GTVs acquired on the inspiratory and expiratory phases 
which was expanded with 5 mm to form the CTV and further with 2 mm to account 
for setup error to form the PTV.  For the ABC group, the CTV was defined as GTV 
plus 5 mm margin and a further 3, 5, and 5 mm in the lateral, anterio-posterior and 
cranio-caudal directions, respectively, to account for internal tumour motion and 
setup error which form the PTV.    
 
From 2008, 4D-simulation using the Philips Brilliance multi-slice CT scanner was 
used for tumour movement evaluation and treatment planning lineation.  The 
respiratory phase was tracked using an infra-red optical system (RPM system, 
Varian).  An infra-red marker was placed on the xipoid of the patient for respiratory 
tracking.  A spiral scan was performed to cover the whole lungs.  The scan was 
acquired at a sufficiently low table speed (low pitch) for any scanned voxel to remain 
within the detector collimation throughout the complete breathing cycle.  The 
source data and the respiratory signal were retrospectively sorted by phase and 
reconstructed to produce the 4D CT images.  Each 4D-CT data set was comprised 
of ten 3D CT images spaced equally among the respiratory cycle.  CT scan with 
slice thickness of 3 mm with no spacing was performed.  As previously stated, 
suitable patients will be selected for DIBH treatment.  For cases with peak to peak 
tumour movement of less than 1 cm, the IGTV was defined with the MIP image set, 
and treatment was performed with free breathing.  Treatment planning was 
performed with the iPlan Stereotactic Planning system (BrainLab Ltd).  Treatment 
outcomes of cases performed from 2000 to 2004 were reported by Ng et al (2009).  
The patient disease characteristics and the applied treatment schemes are listed in 
table 3.1. 
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Table 3.1 Patient disease characteristics and treatment schemes in TMH from 2000 to 
2010. 
 Histology Stage Admission. 
year 
Screening 
for tumour 
motion 
Treatment ITV definition 
1 NSCLC T2N0M0 2000 nil FB GTV + max. motion 
3 Aden T1N0 2001 nil FB GTV + max. motion 
4 Aden T1N0 2001 nil FB GTV + max. motion 
6 Aden T1N0 2002 nil FB GTV + max. motion 
7 Aden T1N0 2002 nil FB GTV + max. motion 
8 SCC T2N0M0 2002 nil FB GTV + max. motion 
9 Aden T1N0 2003 nil FB GTV + max. motion 
10 Aden Lung Sec. 2003 nil FB GTV + max. motion 
11 SCC T1N0 2003 nil FB GTV + max. motion 
12 SCC T2N0M0 2004 nil FB GTV + max. motion 
13 Aden T1N0M0 2004 nil FB GTV + max. motion 
14 NSCLC T2N0M0 2004 nil FB GTV + max. motion 
15 Aden  2004 nil FB GTV + max. motion 
16 Aden T2N0M0 2004 Flu. DIBH GTV + residual motion* 
17 NSCLC T1N0 2004 Flu. DIBH GTV + residual motion* 
18 Aden T1N0 2004 Flu. DIBH GTV + residual motion* 
19 NSCLC T2N0M0 2004 Flu. FB GTV + max. motion 
20 SCC T1N0 2004 Flu. DIBH GTV + residual motion* 
21 NSCLC  2005 Flu. FB GTV + max. motion 
22 Aden Lung Sec., 2005 Flu. DIBH GTV + residual motion* 
23 Aden T1N0 2005 Flu. DIBH GTV + residual motion* 
24 Aden T1N0 2005 Flu+RGCT FB IGTV (RGCT) 
25 Aden T1N0 2005 Flu+RGCT FB IGTV (RGCT) 
26 NSCLC  2005 Flu+RGCT FB IGTV (RGCT) 
27 Aden T1N0 2005 Flu+RGCT FB IGTV (RGCT) 
28 NSCLC  2005 Flu+RGCT FB IGTV (RGCT) 
29 Aden T1N0 2005 Flu+RGCT FB IGTV (RGCT) 
30 NSCLC T1N0 2006 Flu DIBH GTV + residual motion* 
31 Aden T2N0 2006 Flu+RGCT FB IGTV (RGCT) 
32 NSCLC  2006 Flu DIBH GTV + residual motion* 
33 Aden T1N0 2006 Flu DIBH GTV + residual motion* 
34 Aden T1N0 2006 Flu+RGCT FB IGTV (RGCT) 
35 SCC T1N0 2007 Flu+RGCT FB IGTV (RGCT) 
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36 Aden T1N0 2007 Flu+RGCT FB IGTV (RGCT) 
37 SCC T1N0 2007 Flu DIBH GTV + residual motion* 
38 Aden T1N0 2007 Flu DIBH GTV + residual motion* 
39 Aden T1N0 2007 Flu+RGCT FB IGTV (RGCT) 
40 Aden T1N0 2008 Flu+4DCT FB IGTV (MIP) 
41 SCC T1N0 2008 Flu+4DCT FB IGTV (MIP) 
42 Aden T1N0 2009 Flu+4DCT DIBH GTV + residual motion* 
43 SCC T1N0 2009 Flu+4DCT FB IGTV (MIP) 
44 Aden T1N0 2009 Flu+4DCT DIBH GTV + residual motion* 
45 Aden T1N0 2009 Flu+4DCT DIBH GTV + residual motion* 
46 Aden T1N0 2009 Flu+4DCT FB IGTV (MIP) 
47 Aden T1N0 2009 Flu+4DCT DIBH GTV + residual motion* 
48 SCC T1N0 2009 Flu+4DCT FB IGTV (MIP) 
49 Aden T1N0 2010 Flu+4DCT FB IGTV (MIP) 
 
NSCLC:   non-small cell lung carcinoma 
SCC:   squamous cell carcinoma 
Aden:   adenocarcinoma 
Flu:  assessment of tumour motion using x-ray fluoroscopy  
Flu+4DCT:  assessment of tumour motion using both fluoroscopy x-ray and 4DCT  
DIBH:   deep inspiration breath hold 
FB:    free breathing 
GTV + max. motion:  treatment margin in range of 1to 2 cm depending on tumour 
movement is added to GTV to form the CTV/PTV 
GTV + residual motion*:  The ITV was defined based on the residual tumour motion 
during DIBH and the PTV margin also accounts for the residual 
tumour motion as reported in the study by Wong et al
 
2010 
IGTV (RGCT):  internal gross target volume (IGTV) was defined with the respiratory gated 
CT (RGCT) at both inhale and exhale phases.  
IGTV (MIP):  IGTV was defined with the MIP image set 
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3.2   4D Dose Study  
3.2.1  Case Selection 
From 2008 to 2010, ten patients who were diagnosed with stage I lung cancer 
underwent four-dimensional CT simulation for hypo-fractionated radiation therapy in 
Tuen Mun Hospital (TMH), Hong Kong (Patients P40-P49 in Table 3.1).  When 
using 4DCT imaging to assess tumour movement and consequently to process 4D 
dose calculation based on DIR, stable breathing and consistent respiratory 
performance is a pre-requisite.  Cases which were selected for the study were 
screened according to breathing regularity in order to achieve low-noise CT imaging 
for delineation of the tumour in various respiratory phases. Since the 4D CT images 
applied in this study were sorted by the time phase at each respiration cycle, the 
regularity of breathing rate would be important for the control of imaging 
reconstruction.  The breathing rate regularity was assessed by measuring the length 
of every respiration cycle during 4D CT scanning. Cases with standard deviation (SD) 
of the mean breathing rate less than 10% (range: 6.1% - 9.7%) were included in this 
study.  Although the amplitude variation was not assessed in the study, it was 
however presumed to be correlated with the periodic fluctuation as large variation in 
amplitude with constant respiratory frequency is rarely observed in practice.     
Examples of regular and irregular breathing patterns are shown in figure 3.1a and 
3.1b, respectively.  The studied cases were also chosen for the patient group with 
well defined GTV, which was usually the case with adenocarcinoma confirmed by 
histology.  As a result, seven out of the ten cases were included (P40, P42-P45, P47, 
P49 in table 3.1), and of these, four cases were treated with the DIBH technique. Two 
additional cases (case 8 and 9) were provided by the Clatterbridge Cancer Centre 
(CCC), UK.  For the CCC group, the patients received coaching in order to 
maintain a regular breathing pattern, which was confirmed during CT scanning.  
However, the breathing stability was not assessed for the CCC group, as data were 
anonymized and the respiratory surrogate signal could not be retrieved at the time of 
study.  Each 4D-CT data set of the CCC group comprised six 3D CT images spaced 
equally among the respiratory cycle. The quality of 4D CT image which was 
considered may affect the performance of the IM was confirmed by the study of 
matching index which was performed in Chapter 2.2. 
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Figure 3.1 a Example of a regular breathing pattern 
 
 
 
Figure 3.1 b Example of an irregular breathing pattern 
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Table 3.2 lists the characteristics of the tumour in terms of tumour size, location, 
magnitude of movement and histology. The variation of breathing rate obtained over 
the period of CT scan was also evaluated.  For all cases, the mean GTV volumes 
contoured in 3 different breathing phases (i.e. inhale, exhale and mean tumour 
position) ranged from 1.42 cc to 17.89 cc (2
nd
 column, Table 1) with small standard 
deviations (SD).  The resultant tumour movements defined by the quadratic sum of 
the maximum movement along the three axes ranged from 1.2 – 10.5 mm.  
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Table 3.2 Patients’ disease characteristics and treatment parameters for individuals of the study 
 Patient 
(patient 
number of 
Table 3.1) 
* GTV 
mean ± std 
(cc) 
Tumour 
Resultant 
Displacement 
(mm) 
Histology 
Location 
 
Breathing rate 
Variation 
( %100x
Mean
STD
 ) 
Treatment 
Modality 
1  (P42) 1.42±0.07 6.0 AC. LUL 3.4% DIBH 
2  (P40) 1.93±0.06 4.4 AC LUL 9.5% FB 
3  (P45) 3.00±0.14 4.0 AC RLL 9.8% DIBH 
4  (P44) 6.74±0.19 1.2 AC LUL 8.5% DIBH 
5  (P47) 4.06±0.18 4.5 AC RUL 6.4% DIBH 
6  (P43) 17.89±0.33 6.6 SCC RLL 9.7% FB 
7  (P49) 12.80±0.54 3.8 AC LUL 3.3% FB 
8 5.5±0.47 9.2 unknown LUL unknown FB 
9 12.40’±1.47 10.5 unknown LLL unknown FB 
 
Histology:  AC: adenocarcinoma;   SCC:  squamous cell carcinoma; 
Location:   LUL: left upper lobe;  RLL:  right lower lobe;    RUL:  right upper lobe;   LLL: left lower lobe; 
* GTV:    The mean volume of GTVs delineated at the inhale and exhale phases and the temporal mean tumour position.
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3.2.2  Implementation of 4D Dose Calculation 
In principle, the 4D dose over the tumour volume can be calculated by converting the 
3D spatial dose distribution to the 4D spatio-temporal dose distribution. Using the 
GTV as the planning target, by computing the accumulated dose (4D dose) over the 
GTV volume, the actual dose coverage over the tumour volume resulting from 3D 
dose planning can be revealed.  
 
The 3D dose planning was performed on the reference CT selected from the 4D-CT 
set with the GTV as the planning target.  The GTV was manually delineated using a 
lung window (1000, - 500 Hounsfield units) and served as the source data for 
deformable image registration using IM.  In order to minimize the dose volume at 
the low dose region, the margin of beam aperture was limited to 1 mm – 1.5 mm for 
dose planning. As the beam penumbra ranged from 3.2 mm – 3.5 mm, the 85% 
isodose would normally encompassed ≥ 99.5% planning target volume. In this study, 
a prescription of 20Gy was applied at 85% isodose normalized to the isocentre, 
which was defiend at the geometric centre of the GTV, to enclose ≥ 99.5% tumour 
volume.  Treatment planning with radiation dose delivered to the GTV using 
micro-multileaf collimators (M3, BrainLab Ltd, Germany) with single or multiple 
coplanar conformal arc/arcs was performed.  Since the target dose distribution in 
terms of dose conformity and dose heterogeneity could be affected by the beam 
aperture, similar aperture margins ranging from 1.0 - 1.5 mm (larger margin would 
be required for a less regular shaped target) were applied for all cases.  To process 
4D dose calculation, the 3D dose distribution at each respiratory phase was formed 
by re-applying the planning parameters and the monitor units obtained from the 
reference plan to each set of 4D-CT images, and recalculating the dose with a 
heterogeneity correction.  The pencil beam algorithm implemented in the iPlan 
planning system (V.4.1.2 BrainLab Ltd, Germany) was applied for dose calculation.  
An algorithm that account for lateral electronic disequilibrium would be preferable, 
but was not available at the time of this study.  However, since dose plans for 
comparison were performed under the same conditions, the influence of lateral 
electronic disequilibrium on the radiation planning using pencil beam between the 
dose plans was considered to be comparable.  The 3D dose plan obtained from each 
of the 4D-CT data set was imported into the tool box for 4D dose processing as 
described in Chapter 2.  
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The procedure for 4D dose calculation is illustrated in figure 3.2.  An example is 
shown with the planning CT taken at the end-exhale phase (50%).  Figure 3.2a 
shows the 3D dose distribution obtained at the end-inhale phase (0%), the blue 
contour indicates the original location of the GTV captured on the reference CT 
(50%).  The large discrepancy in location between the dose colour-wash and the 
GTV shown on the CT image clearly demonstrates the effect of tumour motion on 
the accumulated dose.  Using the functions IM, DE-DOSE-REG and 
AUTO-CERR-DOSE, the 4D doses acquired at each individual temporal phase from 
0% to 90% (TD 0%-90%) and the GTV dose volume histogram of each are shown in 
figure 3.2b.  The resultant 4D dose distribution over the tumour in a complete 
respiratory cycle is presented in figure 3.2c.  Figure 3.2d demonstrates the 
difference on dose coverage of GTV between the original 3D dose plan and the 
resultant 4D dose using dose volume histogram.  Due to the significant tumour 
movement, the V20Gy which denotes the GTV coverage by the prescription dose 
(20Gy) was 60% of the GTV volume, and the minimum dose (Dmin) received by the 
GTV was 70% (14.02 Gy) of the original planning dose (20 Gy), as a result of 4D 
dose distribution
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Figure 3.2 Procedure of 4D dose calculation. The blue contour indicates the original location of the GTV with dose plan performed at the 
exhale-phase, tumour shift shown at the inhale-phase (fig. 3.2a). By summing the time-weighted received dose of GTV at different phases 
(fig.3.2b), the actual resultant doses received by the GTV was obtained (fig.3.3c). DVHs of GTV in 3D and 4D were compared (fig 3.2d).   
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CHAPTER 4 
 
DOSE PLANNING OPTIMIZATION BY MINIMIZING THE INTERNAL 
TARGET VOLUME 
 
4.1 Definition of Classical Internal Target Volume 
The treatment volume is considered to be the crucial factor for maximizing the 
therapeutic ratio since it affects the degree of radiation induced toxicity and hence 
the potential for dose escalation.  Minimizing the treatment volume is therefore 
essential for enhanced treatment.  The treatment volume is derived from the GTV, 
ITV, CTV and PTV.  The GTV and CTV volumes are restricted by the pathological 
definition and the PTV which accounts for setup error depends on the technical 
implementation by individual centres.  Reducing the internal margin without 
compromising dose coverage to the target is the aims in order to minimize the 
treatment volume.  In this study, a new internal target volume was proposed to serve 
such a purpose; its efficacy was assessed using the classical ITV as a reference.  In 
this study, the classical ITV, namely cITV was defined without microscopic margin.  
The cITV was defined by summing the volumes of the morphed GTVs generated on 
the CT 10% - 90% using CT 0% as the source image.  Since the morphed GTV could be 
different with various source images, the discrepancies among the cITV volumes 
using different reference phases as the source images were evaluated.  Using the 
cITV as the planning target, the planning dose volume included >99.5% target 
coverage denoted as cITV100%.  The definitions of cITV and cITV100% are 
illustrated in Figure 4.1. 
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Figure 4.1 Definition of cITV and cITV100%. The cITV was defined by summing the volumes of the morphed GTVs generated on the CT 10% - 90% 
using CT 0% as the source image. With cITV as the planning target, the planning dose volume included >99.5% target coverage denoted as 
cITV100%. 
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4.2  Introduction of Inverse Internal Treatment Volume (iITV) – A new 
concept of ITV derived from 4D dosimetry 
4D dose calculation using the tool box developed in this work has been described in 
Chapter 3.2, in which the percentage target coverage by the prescription dose of 20 
Gy (V20Gy) and the minimum 4D dose over the target volume (Dmin) were defined.  
Since the dose volume enclosed by the Dmin isodose also determines the dose volume 
which provides the entire dynamic coverage of the GTV, it corresponds to the 
conceptual requirement of the classical ITV.  Therefore, by applying the 
prescription dose to Dmin (ie increasing the prescription dose from 20 Gy to 20/14.02 
= 28.6 Gy), 100% coverage of the GTV by 20Gy would be achieved. Thus, the 
new 3D prescription dose volume (enclosed by the 20Gy isodose level) presented on 
the renormalized 3D dose plan provides a complete dynamic coverage of the GTV 
and defines the ITV of the study.  In contrast to the classical ITV which is 
determined before dose calculation, the proposed ITV is derived from the 4D dose 
calculation and it is therefore denoted as the inverse ITV (iITV).   The iITV defined 
in the 3D dose plan, despite it being initially derived from the 4D dosimetry (from 
the Dmin), was intended for enabling comparison with the 3D dose volume 
generated from the conventional approach for evaluation of potential benefit in terms 
of a reduction of dose volume.  The definition of iITV is illustrated in Figure 4.2. 
The V20Gy and iITV obtained from dose plans performed at different breathing phases 
provide a quantitative measure of the dose effects in relation to the magnitude and 
characteristics of tumour motion and tumour size.  Such will be discussed in the 
following studies.  
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Figure 4.2  Defining the iITV with the dose volume enclosed by Dmin. The 100% target coverage with prescription dose of 20Gy is obtained by 
applying 20Gy to Dmin, by increasing the prescription dose from 20Gy to 20/14.02 = 28.6Gy. 
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4.3  Effect of Phase-Specific Dose Planning on Target Coverage and the Volume 
of iITV 
 
4.3.1  Introduction 
In general, the amount of target coverage is significantly associated with the 
magnitude of tumour movement, however a well-chosen CT phase from the 4D CT 
scan for treatment planning plays an important role in optimizing dose planning   
Previous studies (Engelsman et al. 2001; Witte et al. 2004)
 
have shown that if the 
tumour is irradiated at its average position during the respiratory cycle, optimal dose 
coverage would be obtained even if the tumour is not fully within the high-dose 
region during certain parts of the breathing cycle due to the presence of the 
wide-beam penumbra.  However, dose planning is usually performed at the 
end-inhale or end-exhale phases.  Whilst the inhale phase creates a larger lung 
volume which would minimize normal tissue irradiation, the exhale phase would 
result in the most stable and reproducible target position (Balter et al. 1998; Wu et al. 
2010 ).  In our study, the most effective respiratory phase for dose planning was 
assessed with the maximized target coverage and the minimized iITV volume.  
 
4.3.2 Methods 
For each case, three dose studies were performed with the planning CT selected at 
end-inhale (PLCTin), end-exhale (PLCTex) phases and at the temporal mean tumour 
position (PLCTmean).  The V20Gy and iITV at the corresponding phases, namely  
Vin 20Gy,, Vex 20Gy, Vmean 20Gy, and iITVin, iITVex, iITVmean, respectively, were then 
determined.  For the dose plan performed at the temporal mean tumour position, the 
planning CT was selected among all CT bins using the average intensity projected 
(AIP) CT images as reference.  Thus, the tumour position shown on each CT phase 
was compared with that of the AIP set, the CT set with the tumour at the most 
comparable position was selected for the planning CT.  The dose volumes iITVin, 
iITVex and iITVmean were consequently compared with each other.   
 
4.3.3 Results 
For all cases, the mean GTV volumes of the three phase-specific dose plans ranged 
from 1.42 cc to 17.89 cc (2
nd
 column, Table 4.1) and the standard deviations were 
relatively small.  The peak to peak tumour movements were 0.5 mm – 5.8 mm, 0.5 
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mm – 8.3 mm, 0 mm – 9.0 mm in the lateral, anterio-posterior and cranio-caudal 
directions, respectively, and the resultant displacement ranged from 1.2 mm to 10.5 
mm. (3
rd
 column, table 4.1).  The inadequate target coverage as a result of tumour 
motion was clearly revealed by the 4D dose distribution.  The V20Gy and the volume 
of iITV obtained in the phase-specific dose plans for all cases are varied and depicted 
in columns 2 – 4 and columns 8 – 10 of table 4.2, respectively.  Among all 
phase-specific dose plans, the V20Gymean provides the maximum or over 93% target 
coverage in majority of the cases (cases 1 -7) and the iITVmean which has the smallest 
volume for all the case suggests that dose planning performed at the tumour mean 
position generally provides the optimal target dose coverage. The reasons for 
maximum target coverage maximizations not obtained with V20Gymean in cases 8 and 
9 are explained in chapter 5.2.
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Table 4.1 Treatment planning parameters for phase-specific dose studies 
Patient 
GTV (cc) 
mean ± std 
max Pk-Pk 
(mm) 
cITV (cc) 
mean ± std 
PLCTin 
(%) 
PLCTex 
(%) 
PLCTmean 
(%) 
1 1.42 ± 0.07 5.8 (LAT)  1.6 (AP)  0.3 (CC)   6.0 (RES) 3.17± 3.3% `0 50 20 
2 1.93 ± 0.06 0.5 (LAT)  2.6 (AP)  3.5 (CC)   4.4 (RES) 2.80 ± 0.6% 0 60 30 
3 3.00 ± 0.14 0.5 (LAT)  2.6 (AP)  3.0 (CC)   4.0 (RES) 4.42 ± 4.1% 0 50 80 
4 6.74 ± 0.19 1.1 (LAT)  0.5 (AP)  0 (CC)     1.2 (RES) 8.66 ± 1.4% 0 60 60 
5 4.06 ± 0.18 1.1 (LAT)  3.2 (AP)  3.0 (CC)   4.5 (RES) 6.36 ± 2.4% 0 60 20 
6 17.89 ± 0.33 2.1(LAT)  1.6 (AP)  6.0 (CC)   6.6 (RES) 22.23 ± 1.4% 0 60 60 
7 12.80 ±0.54 1.5(LAT)  3.5 (AP)  0 (CC)     3.8 (RES) 17.04 ± 1.9% 0 50 80 
8 5.5 ± 0.47 1.5 (LAT)  1.5 (AP)  9.0 (CC)   9.2 (RES) 10.74 ± 4.3% 0 50 33 
9 12.40 ± 1.47 2.4(LAT)  8.3 (AP)  9.2 (CC)   10.5 (RES) 18.52 ± 1.7% 0 50 16 
 
GTV: gross tumour volume.   
cITV: classical internal target volume.   
max pk-pk:  maximum peak to peak tumour movement; LAT, AP, CC and RES denotes lateral, anterior-posterior, cranio-caudal and resultant 
displacements., respectively.  
PLCTin, PLCTex, PLCTmean:  planning CT selected for the phase-specific studies at inhale, exhale and tumour mean position, respectively.   
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Table 4.2  
   
CASE 
Vin 20Gy 
(%) 
Vex 20Gy 
(%) 
Vmean 20Gy 
(%) 
Dminin 
(Gy) 
Dminex 
(Gy) 
Dminmen 
(Gy) 
iITVin 
(cc) 
iITVex 
(cc) 
iITVmean 
(cc) 
cITV100% 
(cc) 
Diff (%) 
iITVmean  vs  cITV100% 
% coverage of cITV 
by iITVmean 
1 63.1 57.4 71.5 14.02 14.72 15.92 4.76 5.03 3.90 4.86 - 19.8 86.4 
2 91.0 85.2 95.9 18.02 17.02 17.88 4.23 4.58 3.96 4.39 -9.8 94.6 
3 73.0 80.0 89.2 12.57 17.27 17.48 11.75 6.64 5.17 7.38 -29.9 90.8 
4 96.6 97.7 97.7 18.13 18.27 18.27 12.06 11.1 11.1 13.64 -18.6 98.3 
5 92.8 94.6 92.9 16.42 17.45 18.42 13.63 10.43 7.34 10.16 -27.7 92.4 
6 90.7 96.7 96.7 14.82 18.67 18.67 37.93 26.81 26.81 28.16 -4.8 98.6 
7 95.7 99.1 95.6 17.17 18.77 18.48 28.00 24.44 23.93 24.49 -2.3 98.8 
8 83.2 60.4 79.5 15.47 13.13 17.5 20.17 20.99 14.18 17.49 -19.3 84.6 
9 66.9 90.4 84.0 8.23 13.63 14.77 79.85 38.5 28.5 26.36 +8.1 97.0 
 
V20Gy:  accumulated dose coverage of GTV by 20Gy (prescription dose) as a result of 4D dose evaluation. V20Gy expressed in terms of percentage of GTV 
volume 
Dmin:  minimum dose received by the GTV as a result of 4D dose evaluation.  
iITV:  inverse internal target volume  
cITV:  classical internal target volume.   
cITV100%:  prescription dose volume to the cITV.   
In, ex, mean:  values obtained in the phase-specific studies performed at inhale, exhale and tumour mean position, respectively. 
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4.4  Internal Target Volume Comparison – between iITV and cITV  
 
4.4.1 Methods 
To demonstrate whether the internal target volume could be effectively minimized 
according to the concept of iITV, the dose volume defined by the iITV was compared 
with the dose volume generated by the classical ITV (cITV) during 3D dose planning.  
The cITV100% which defines the dose volume generated by the cITV with >99.5% 
prescription dose coverage was compared with the volume of the iITVin , iITVex and 
iITVmean. 
 
4.4.2. Results 
Depending on the magnitude of tumour movement, the volume of cITV were 2 to 3 
times that of the GTV volume, ranging from 2.80 cm
3
 to 22.23 cm
3
 (column 4, table 
4.1).  As considering that if there would be significant variation between the 
volumes of cITV derived from different respiratory phases could affect the result of 
the study. The cITV volumes generated from three studied reference phases were 
evaluated and discrepancies among those were found to be small.  The variations 
(SD / mean volume) among the three studies were ranged from 0.6% to 4.1% for all 
cases.  Our results show that the iITV reduces the internal target volume compared 
with that defined classically.  The iITVmean, which has the minimum volume among 
all iITVs was found to be smaller than the dose volume of cITV100%.  The volume 
reduction ranged from 2.3 % to 29.9% (mean: 16.5%) for all cases except case 9, in 
which the dose volume of iITVmean was 8.1% greater than that of cITV100% (the cause 
is addressed in chapter 6.2).  The results are shown in columns 8 – 12 of table 4.2.  
The difference between the GTV, cITV, iITV and cITV100% is illustrated 
geometrically in figure 4.3.  The iITV (in green) defining 100% dynamic dose 
coverage of the GTV (in red) did not completely cover the cITV (in orange). This 
incomplete coverage was observed in all cases.  The volume coverage of cITV by 
the iITVmean ranged from 84.6% to 98.8% (93.5 ± 4.6%) of the cITV volume 
(column 13, table 4.2).  Such a result demonstrates that dose coverage of the entire 
range of the tumour motion which would be applied in classical ITV during dose 
planning may not be necessary.  
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Figure 4.3 The geometric difference between the GTV, cITV, iITV and cITV100% is illustrated. 
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4.5 Dose Properties Comparisons between Studies with Dosimetric Indices 
To enable unbiased comparison of the dose studies, the 3D dose planning protocol 
for all studied dose plans was conformed to the RTOG 0236 guidelines (Michaiski et 
al 2009). These guidelines suggest that planning doses are normalized to the centre of 
the target volume and prescribed to between the 60% – 90% isodose level. The 
conformity of target coverage defined as the ratio of the volume of the prescription 
isodose to the volume of planning target should be less than 1.2. The protocol 
recommends that at least 95% of the planning target volume (PTV) should be 
covered by the prescription isodose surface, and that 99% of the PTV receive at least 
90% of the prescription dose. However, in our study, the proposed iITV was 
inversely derived from the resultant 4D dose accumulated in the moving tumour. 
Hence, dose was prescribed directly to the GTV with a target coverage of more than 
99.5%.  
 
Although similar dose planning parameters were attempted for all four plans (ie 
iITVin , iITVex , iITVmean , cITV), the shape, size and location of the planning target 
were not the same because of the non-rigid transformation of the tumour during the 
breathing cycle. The planning parameters (eg. beam aperture margin, number of 
conformal arcs, etc) inevitably had to vary in order to achieve the optimal dose plan 
for each study. Similarity in dose properties between the four plans was however 
confirmed by employing the following dosimetric indices; target coverage index 
(TCI) (Lomax et al, 2003), conformity index (CI)
 
(Lomax et al, 2003; Shaw et al, 
1993) and dose heterogeneity index (HI)
 
(Lomax et al, 2003; Shaw et al, 1993). The 
TCI specifies the percentage coverage of the prescription dose, whereas the CI 
indicates the amount of prescription dose volume as a function of the planning target. 
The HI defines the ratio of the maximum target dose to the prescription dose.  
 
The similarity in dose properties among the four dose plans was verified with the 
dosimetric indices. The CI values at 95% and 99.5% target coverage were assessed. 
The mean CI values of the three phase-specific dose plans ranged from 1.50 to 1.80 
and 1.20 to 1.62 at 99.5% and 95% target coverage, respectively (1
st
 column of table 
4.3). The CI values of cITV ranged from 1.15 to 1.67 and 1.12 to 1.31 at 99.5% and 
95% target coverage respectively (5
th
 column of table 4.3). The mean and standard 
deviation of TCI and HI of the four dose plans for all cases are listed in columns 3 - 4 
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of table 4.3. The very low standard deviation of the TCI for the four studied plans 
confirms that all 3D dose plans are similar in terms of target coverage for dose 
comparison. In addition to equivalent target coverage, the small standard deviations 
of CI and HI were 2% – 3% and 0 – 1% of their respective mean values suggesting 
that the dose properties and the dose distributions were similar among all dose plans.  
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Table 4.3 The dose properties among the phase-specific dose plans and dose plans of cITV were compared with the dosimetric indices of CI, TCI 
and HI. 
Patient CI (CI 95%)  of   
3 phase-specific dose plans 
 
(mean ± std)  
TCI (%) of   
all dose plans 
 
(mean ± std)  
HI of  
all dose plans 
 
(mean ± std) 
CI (CI 95%) 
of 
cITV 
1 1.80 ± 0.04  (1.33 ± 0.15) 99.7 ± 0.1 1.21 ± 0.01 1.53 (1.28) 
2 1.95 ± 0.18  (1.24 ± 0.08) 99.8 ± 0.2 1.22 ± 0.02 1.57 (1.26) 
3 1.86 ± 0.04  (1.62 ± 0.12)) 99.5 ± 0.0 1.20 ± 0.01 1.67 (1.31) 
4 1.65 ± 0.04  (1.20 ± 0.06) 99.8 ± 0.0 1.19 ± 0.00 1.58 (1.19) 
5 1.84 ± 0.04  (1.39 ± 0.03) 99.8 ± 0.0 1.22 ± 0.01 1.39 (1.29) 
6 1.50 ± 0.03  (1.29 ± 0.11) 99.8 ± 0.2 1.21 ± 0.01 1.15 (1.18) 
7 1.67 ± 0.05  (1.50 ± 0.07) 99.6 ± 0.1 1.20 ± 0.01 1.39 (1.30) 
8 1.69 ± 0.01  (1.34 ± 0.05) 99.8 ± 0.1 1.22 ± 0.00 1.63 (1.20) 
9 1.53 ± 0.01  (1.26 ± 0.11) 99.8 ± 0.2 1.24 ± 0.02 1.42 (1.12) 
CI: Conformity index evaluated at 99.5% target coverage. 
CI 95%: Conformity index evaluated at 95% target coverage 
TCI: Target coverage index. 
HI: Dose heterogeneity index
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CHAPTER 5 
 
DOSIMETRIC EFFECT OF TUMOUR MOTION  
 
5.1    Factors Associated with Tumour Size and Magnitude of Movement 
 
5.1.1  Introduction 
In general, the magnitude of tumour motion is considered to be the prime factor in 
obtaining target coverage.  A motion-related treatment margin (Balter et al. 1998; 
Wong et al. 2010) is generally applied for treatment planning.  Several studies have 
suggested that the treatment margin may be derived from 4D contouring or the 
probability distribution of the target positions.  Rietzel et al
 
(2006) used 4D CT to 
characterize tumour motion in order to define the treatment volume.  Ekberg et al 
(1998) suggested a margin formula of 1.64σ, where σ denotes the combined 
deviation of tumour motion and treatment setup corresponding to the nominal 
probability of the target position of 90% in each of the three dimensions.  van Herk 
et al (2000) introduced a margin recipe of 2.5Σ+ 0.7σ’, where Σ denotes systematic 
errors introduced by treatment preparation variations due to setup error on CT scan 
and organ motion as well as delineation error, and σ’ denotes random errors occur 
due to tumour motion and day-to-day setup error. The recipe was derived from the 
dose-population histograms to ensure that 90% of the patient population receive 95% 
of the prescription dose.  Both formulae were applied regardless of the tumour size.  
The dosimetric effects on factors associated with tumour size and tumour motion are 
examined in this section.   
 
5.1.2 Methods 
To assess the efficiency of margin determination based on the magnitude of tumour 
motion, the correlation between actual target coverage as a result of 4D dose 
evaluation and the magnitude of tumour displacement was studied.  The minimum 
V20Gy of all phase-specific dose plans which indicates the extremity of target missing 
encountered during the respiratory cycle was plotted against the resultant magnitude 
of tumour displacement and the degree of correlation between the two factors was 
  54 
assessed by using a linear least –squares fit and the Pearson correlation coefficient 
(R
2
).   
 
5.1.3 Results 
The low value of R
2
 of 0.4671 as shown in Figure 5.1 indicates poor linear 
correlation between the target coverage and the magnitude of tumour movement.  
However, the degree of target coverage was found to be associated with the 
combined factors of motion magnitude and tumour size.  Significant target missing 
was found for smaller tumours with similar movement to large tumours as can be 
seen in table 5.1.  For instance, more severe target missing was found with case 1 
with a tumour size of 1.42 cc compared with case 6 with tumour size of 17.89cc 
while in both cases the resultant movement was about 6 mm.  The difference in 
target coverage between the two cases was found to be 35.4% (Vex 20Gy of 57.4 % for 
case 1, Vin 20Gy of 92.8% for case 6) by comparing the minimum V20Gy obtained in 
the two cases.  Similar findings were observed between case 3 (tumour size of 3.0 
cc) and case 7 (tumour size of 12.8 cc), case 2 (tumour size of 1.42 cc) and case 5 
(tumour size of 4.06 cc) with differences in target coverage of 22.7% and 7.6% with 
tumour movement of ~4.0 mm and ~4.5 mm, respectively (see Table 5.1).  The 
phenomenon was found to be more apparent for cases with a large discrepancy in 
tumour size and with the same magnitude of motion.                                               
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Figure 5.1 The minimum target coverage plots against the magnitude of tumour movement. 
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Table 5.1 The relationship between target dose coverage and tumour size and magnitude of tumour movement. 
Case resultant movement (mm) 
√(APmax
2
 +LRmax
2
 +SImax)
2
 
tumour size (cc) Least target Coverage 
(V20Gy) 
4 1.2 6.74 96.6% 
7 3.8 12.8 95.7% 
3 4.0 3.0 73.0% 
2 4.4 1.93 85.2% 
5 4.5 4.06 92.8% 
1 6.0 1.42 57.4% 
6 6.6 17.89 90.7% 
8 9.2 5.5 60.4% 
9 10.5 12.4 66.9% 
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5.2     Factors Associated with Characteristic Motion Trajectory  
5.2.1 Introduction 
To further explore the factors involved in target coverage maximization, the 
influence on target coverage in relation to the characteristic of the tumour trajectory 
was also assessed.  This was performed by studying V20Gy obtained from the three 
phase-specific dose plans with respect to the nature of tumour motion trajectory for 
each case.  
 
5.2.2 Method 
The tumour trajectory was determined from tumour motion vector plots, which was 
set at the peak along the direction with maximum displacement, as a function of the 
respiratory phase. The path of maximum displacement was selected in order to 
maximize the trajectory effect on dose coverage.  
 
5.2.3 Results 
The degree of target coverage maximization was demonstrated to be affected by the 
characteristics of the tumour motion.  Figure 5.2 shows the V20Gy obtained from the 
three phase-specific dose plans of all cases (except case 4 due to the insignificant 
tumour movement) and with tumour trajectories illustrated in each case.  The results 
indicated two types of tumour trajectory; the sinusoidal-like and a “flat-top” 
sinusoidal.  Substantial target coverage maximization was found with the latter type, 
as shown in cases 2 – 7 with Vmean 20Gy  ranging from 89.2% – 95.9% compared to 
71.5% to 84.0% for cases 1, 8, 9, in which tumours moved in a sinusoidal-like 
trajectory.  This can be explained, for the case of a sinusoidal-like trajectory full 
target irradiation is obtained only over a relatively small fraction of the respiration 
cycle, however, for the flat-top sinusoidal trajectory, the tumour stays near the 
end-exhale position for most of the respiration cycle which corresponds to the 
position of the temporal mean.   Hence the temporal-mean dose plan is most 
advantageous for cases with tumour movement in flat-top sinusoidal trajectory.  
This phenomenon is illustrated in Figure 5.3.  A similar effect would be expected 
where hysteresis in tumour motion is evident. Such limitation could become more 
apparent with larger tumour displacement, as even smaller portion of respiration 
would receive full target irradiation. As shown in case 9, where tunmor has the 
largest magnitude of displacement among all cases and in sinusoidal-like movement, 
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treatment volume was not optimized with dose plan performed at the temporal mean 
tumour position, resulting with similar volume of iITVmean (28.5 cc) and cITV100% 
(26.4cc).  Moreover, the volume of iITV is directly related to the value of Dmin, the 
lower the Dmin, the larger the iITV volume. Target with irregular shape is often 
associated with low Dmin due to the low dose received at the pointed area of the 
treatment target, it therefore significantly reduces the Dmin and consequently enlarges 
the iITV volume. Thus apart from the nature of the tumour movement, the degree of 
tumour uniformity may also affect the significance of the target coverage 
maximization using iITV.  In cases 9, the shape of GTV was irregular and contained 
a few spikes. The minimum target dose of 14.77 was received at one of the spike, 
and enclosed 28.5 cc dose volume. Considering that if the spike was not existed, then 
the minimum dose would be increased to 15.5Gy which enclose 26.5 cc dose volume, 
that is almost the same as cITV100% (26.4 cc). The geometric factor concerning the 
significance of iITV for cases 3 was explained in figure 5.4.  
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Figure 5.2 shows the V20Gy obtained from the three phase-specific dose plans of all cases (except case 4 due to the insignificant tumour 
movement) and with tumour trajectory illustrated in each case.  The tumour trajectory is plotted with vector magnitude (1division = 1mm)  
against breathing phase ranged from 0% to 100% in 20% interval. 
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Figure 5.3 Diagram illustrates the temporal irradiation of the target for cases with sinusoidal-like (top) and flat-top sinusoidal (bottom) tumour 
motion trajectory during a breathing cycle. The top diagram shows when the target (in orange) is moving across the radiation filed (region 
confined by the blue dotted line ) in a sinusoidal-like trajectory, full target irradiation is obtained in a relatively small fraction of the respiration 
cycle, while more irradiation is received in the lower diagram.  
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Figure 5.4  The upper diagram shows the Dmin of 14.77 located at the superior spike enclosing 28.5 cc dose volume. The bottom diagram shown 
Dmin increased to 15.5 Gy if the spike is not existed. The % difference in dose volume enclosed by the Dmin of14.77 and of 15.5 Gy could be  
deduced using dose volume histogram.  
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CHAPTER 6 
 
INTRODUCTION OF OPTIMIZED 4D TREATMENT PLANNING 
 
6.1    Determination of Effectual 4D Planning Technique using iITV  
 
6.1.1 Introduction 
The definition of iITV derived from a 4D dosimetric approach is proposed in this 
study, it minimizes the treatment volume by reducing the conventionally defined 
internal treatment margin.  The results of the study indicate that the effectiveness of 
margin minimization depends on the planning (or reference) phase where the iITV 
was generated.  Although dose planning performed at the temporal mean tumour 
position was confirmed to provide the most optimal dose plan with over 95% target 
coverage or the maximum target coverage among all phase-specific dose studies (see 
column 2
nd
 - 4
th
 , Table 4.2), however, the degree of target coverage maximization 
was found to be related to the nature of the target motion trajectory.  The 
temporal-mean dose plan is most advantageous for target travels with a flat-top 
sinusoidal trajectory but is less effective for cases with sinusoidal-like trajectory.  
As for the cases with sinusoidal-like moving trajectory, tumour continuously travels 
along the moving track with initial deceleration until reach to the end inhale and 
followed by acceleration to the end exhale. Hence similar amount of receiving doses 
to the target would be expected with the reference field of radiation defined at any 
phase.  Therefore, there would be no advantage in selecting the planning phase as 
explained in figure 5.3.  
 
Due to the above reasons, the radiation field must cover the entire motion range of 
the tumour in sinusoidal-like movement to ensure the full target coverage (ie. > 
99.5% target volume encompassed by the prescription dose).  Hence instead of 
using GTV, the cITV is applied for the planning target during the 3D dose planning.  
In such an approach, the tumour (ie GTV) would receive a higher radiation dose than 
the prescription dose while it travelled along the high dose region within the beam 
aperture.  As a result, a lower prescription dose would be required to achieve the 
full target dose coverage resulting in a reduction of treatment dose volume.  This 
hypothesis is explained in figure 6.1. 
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Figure 6.1 In the case of sinusoidal-like tumour motion trajectory, cITV applied as the planning target providing entire target coverage and higher 
dose irradiation to the tumour (in orange) while it travels across the high dose region (in red) 
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6.1.2 Methods 
To test the hypothesis and its implications for treatment volume optimization, dose 
planning was studied using cITV as the planning target which encompasses the entire 
dynamic coverage of the tumour, for all cases.  The 3D dose plans as described in 
Chapter 4.1 were re-employed for this study.  Since the generated volume of cITVs 
has been evaluated and shown to be similar with the source image selected from 
different planning phases (column 4, Table 4.1), the planning reference was thus 
selected arbitrarily at the inhale phase for this study.  For the evaluation of 4D dose 
distributions in the target, the 3D target dose at each respiratory phase was obtained 
by re-applying the planning parameters and the monitor units obtained from the 
reference plan to each set of 4D-CT images and recalculating the dose with a 
heterogeneity correction.  The 4D dose distribution over the GTV was traced 
according to the voxel displacement of the GTV during respiration and determined 
by IM as described in Chapter 3.2.2  
 
6.1.3 Results 
The phenomenon described in figure 6.1 was observed in the study.  Figure 6.2 
shows the 3D dose plan of case 9, in which the tumour was displaced uniformly 
along the motion range during respiration (figure 6.2a).   The radiation field covers 
the entire motion range (ie cITV) and the hot dose zone was located near the centre 
of the radiation field (figure 6 2.b).  The dose-volume histogram indicates that the 
GTV received excessive dose above the prescribed dose (20Gy), as over 60% of the 
GTV volume received radiation dose higher than 23.5 Gy at any breathing phases 
(figure 6.2c).  
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Figure 6.2  shows the 3D dose plan of Case 9.  In figure 6.2a, GTV of phases 0%, 16%, 33%, 50%, 67%, 83% shown in yellow, green, orange, 
red, blue, purple, respectively, displace uniformly along the motion range during respiration cycle.  Excessive high dose irradiation to GTV 
volume during most of the respiration cycle is shown in figure 6.2b.  At the breathing phases of 0%, 50% and 33%, the GTV volume of 63%, 
76% and79% respectively received radiation doses of ≥23.5Gy.  The yellow, red and orange colour-wash denote the GTV at breathing phases of 
0%, 50% and 33%, respectively in figure 6.2b.   
 
Figure 6.2 a                     Figure 6.2 b 
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Figure 6.2c  The 3D dose volume histogram depicts the temporal dose distribution of GTV. At each breathing phases the GTV volume ranged 
from 63% to 79% receiving radiation dose of ≥ 23.5Gy during the respiration cycle. (The print out of “violated DVH constraint” referred to the 
constraints of dose planning setting).  
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Figure 6.3 compares the 3D and 4D dose volume histogram for the GTV (green line) 
for case 9.  The Dmin of 21.02Gy being higher than the prescription dose suggests 
that the overwhelming tumour dose resulted from the excessive irradiation at the 
high dose zone.   Using cITV as the planning target, the Dmin was found in all cases 
to be higher than or equal to the prescription dose (20Gy) (column 4, Table 6.1).  
By prescribing at the isodose level of Dmin, the dose volume encompassed by 20Gy 
on the re-normalized 3D dose plan defines the new internal target volume, denoted 
iITVall.  As suggested by the higher dose values of Dmin compared to 20Gy in most 
of the cases, the iITVall is expected to be smaller than the cITV100%.  Table 6.1 
compares dose volumes among the iITVmean, cITV100% (data were extracted from 
columns 10 – 11, Table 4.2) and iITVall for all cases, and showed that the iITVmean 
reduced the dose volume by 16.5% (range from 2.3% to 29.9%) (column 6, table 6.1) 
and iITVall reduced the dose volume by 8.7% (ranged from 0% to 24.9%) (column 7, 
table 6.1), as compared to cITV100%.  Moreover, although the iITVmean reduced dose 
volume in most of the cases, further reduction in volume could be obtained with 
iITVall for the cases with targets in sinusoidal-like motion trajectories (case 1 and 
case 9, see column 8, table 6.1). This result suggests that iITVmean may be more 
effective for flat-top sinusoidal motion trajectory and iITVall for sinusoidal-like 
trajectory for minimizing treatment volume.  
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Figure 6.3 The comparison between 3D and 4D dose volume histogram of the GTV in case 9. 
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Table 6.1  Dose volume comparison among the iITVmean, cITV100% and iITVall for all cases. 
Case cITV100% 
(cc) 
iITVmean 
(cc) 
D min 
(Gy) 
iITVall 
(cc) 
iITVmean 
vs 
cITV100% 
iITVall 
vs 
cITV100% 
iITVall 
vs 
iITVmean 
1 4.86 3.90 20.56 3.65 - 19.8 -24.9 -6.4 
2 4.39 3.96 19.96 4.39 -9.8 0 +10.9 
3 7.38 5.17 20.46 5.87 -29.9 -20.5 +13.5 
4 13.64 11.1 21.36 11.08 -18.6 -18.8 -0.2 
5 10.16 7.34 20.00 10.16 -27.7 0 +38.4 
6 28.16 26.81 20.03 28.16 -4.8 0 +5.0 
7 23.69 23.93 20.02 23.69 -2.3 0 -1.0 
8 17.49 14.18 20.32 16.70 -19.3 -4.5 +17.8 
9 26.36 28.5 21.02 23.75 +8.1 -9.9 -16.7 
 
cITV100%:  prescription dose volume to the cITV. 
iITVmean:  inverse internal target volume derived from the dose plan performed at the temporal mean of tumour movement. 
Dmin:  minimum dose received by the GTV as a result of 4D dose evaluation whereas cITV was applied as the planning target for 3D dose planning. 
iITVall : inverse internal target volume derived from the dose plan with cITV as the planning target 
cITV100% : prescription dose volume of the cITV.
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6.2   4D Treatment Planning Implementation – with treatment margins 
considered 
 
6.2.1 Introduction 
In this study, the concept of iITV has been proposed to optimize treatment by 
minimizing the treatment volume.  In order to simplify the explanation of the 
concept and for the purpose of easy validation (image morphing), at the beginning of 
the study, the GTV was applied as the planning target without accounting for clinical 
(microscopic spread) and setup margins.  To verify whether the concept of iITV 
could be effectively applied for clinical practice where such margins are required, the 
4D doses were evaluated with the planning target including both clinical and setup 
margin.  In the following studies, the treatment doses developed according to the 
proposed 4D planning technique were assessed and compared with those obtained 
using the conventional 3D planning technique, as well as with the immobilized 
treatment techniques using Deep-Inspiration- Breath-Hold which had been applied 
clinically in TMH. 
 
According to the results of the iITV study, the smallest ITV volume was obtained 
with iITVall for cases 1, 4, 7, 9 and iITVmean for case 2, 3, 5, 6, 8 (Table 6.1).  One 
case from each group was re-applied for 4D dose planning study in this section with 
the PTV containing both clinical and setup margins.  The planning target dose and 
the lung dose were evaluated and compared with that obtained from the conventional 
and DIBH techniques.  Since cases 1 and case 3 from each group had undergone 
DIBH treatment, they were selected for this study.    
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6.2.2 Method 
 
6.2.2.1 Definition of PTV for the studies 
 
A.. Conventional PTV  
The conventional PTV (cPTV) is defined according to ICRU 62.  The GTVs which 
are delineated on each phase of the four-dimensional computed tomography (4D-CT) 
image date set were expanded with a clinical margin to form the CTVs (5 mm 
margin was applied in this study).  To explicitly account for the variations in tumour 
position, size and shape, the ITV is constructed by combining the CTVs and 
expanded with setup margin (2 mm was applied in this study) to form the cPTV 
(figure 6.4) 
 
 
Figure 6.4 Definition of cPTV for conventional 3D dose planning 
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B. PTV for Case 1 
As shown by the results of the previous study (on iITV), since the tumour of this case 
moved in a sinusoidal-like pattern, using the cITV as the planning target volume had 
provided the least resultant treatment volume ( iITVall ).  A similar result was 
therefore presumed for treatment while the clinical and setup margins were included 
for dose planning. The cPTV, defined previously (section A), covering the entire 
motion range was employed as the PTV for this case. The cPTV was delineated on 
the planning CT selected at the inhale phase.  The volume of GTV, CTV and PTV 
defined at the reference CT were denoted as GTV_ref, CTV_ref and PTV_ref, 
respectively (figure 6.5).  The resultant 4D doses received by the cPTV and 
PTV_ref were evaluated for the effective treatment volume comparison. 
 
Figure 6.5  cPTV applied as planning target for 4D dose planning study in case 1 
 
 
 
C. PTV for Case 3 
The tumour in this case displaced in a flat-top sinusoidal trajectory during breathing.  
As indicated by the results of previous study, the planning reference taken at the 
temporal mean position achieved the most optimal treatment volume among studies.  
Hence, for the 4D planning study, the planning target volume, denoted PTV_ref, was 
defined with the GTV delineated at the temporal mean tumour position (ie GTV_ref), 
and expanded by 5 mm to form the CTV (ie CTV_ref) and further 2 mm to account 
for setup error.  However, the margin accounting for tumour motion is not included 
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within the treatment volume.  For the purpose of dosimetric comparison with the 
conventional technique, conventional dose planning was performed using cPTV as 
the planning target. (see figure 6.6)
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Figure 6.6 The yellow circle indicates the defined planning volume for the dose studies of conventional planning and 4D dose planning 
 
A. PTV definition of case 3                    B. conventional planning                   C. 4D dose planning study   
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6.2.2.2  4D Dose Planning   
The 4D dose was calculated based on the procedure described in Chapter 3.2.2, and 
with the PTV described above for case 1 and case 3 as the planning target.  The 3D 
dose planning was initially performed on one of the 4D CT sets (reference planning 
phase at 0% for case 1, 30% for case 3).  A prescription of 20Gy was applied to the 
85% or 90% isodose to enclose ≥ 99.5% of the PTV volume.  To evaluate the 4D 
dose over the planning target volume, the PTV_ref at the reference CT served as the 
source data for deformable image registration using IM.  However, the source data 
confined to the PTV_ref region would not be sufficient to look up the eventual 4D 
dose volume enclosed by the Dmin of the PTV_ref. Thus the 4D dose distribution 
beyond the PTV_ref was assessed with source data of IM extended to a region of 
approximately 1 cm from the extremity of the PTV_ref (1cm is determined according 
to the tumour displacement magnitude) in the three dimensions.  The 4D dose 
calculation was processed with the 3D dose distribution obtained at each respiratory 
phase by re-applying the planning parameters and the monitor units employed in the 
reference plan to each set of 4D-CT images, and recalculating the 3D doses with a 
heterogeneity correction.  The 4D dose was then calculated using the 4D dose tool 
box.  As a result of the 4D dose calculation, the Dmin of the PTV_ref can be 
determined by prescribing at Dmin on the original 3D dose plan, complete PTV_ref 
coverage by 20Gy would be achieved.  The new dose volume enclosed by 20Gy 
presented on the renormalized 3D dose plan was compared with the planning dose 
volume obtained from conventional treatment plan with cPTV as the planning target.  
 
6.2.2.3  Lung dose evaluation 
Apart from the evaluation of the effective size of treatment volume, the amount of 
radiation dose delivered to the lung volume was also assessed.  The small variation 
between lung volumes measured at different respiratory phases of within 5% of its 
mean value (Table 6.2) implies that the deformation effect on dosimetric influence on 
lung volume during breathing was insignificant.  Thus, the dosimetric influence 
caused by geometrical changes of lung volume was not accounted for lung dose 
evaluation.  The volume of lungs was assumed to remain constant during the 
breathing cycle.  The mean physical lung dose (LD mean) was calculated based on 
the dose-volume histogram, in which both lungs were considered as one organ and 
the GTV was excluded.  LDmean is given by equations (1) and (2) : 
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LD mean = Σi νi． LDi      (2) 
  
Where LDi  is the physical mean dose received by the partial lung volume (νi ) in dose bin 
i of the dose plans obtained from the mth respiratory phases (m=10 for both cases).  
 
 
Table 6.2  Lung volume of case 1 and case 3. 
 Case 1  Case 3 
0% 2583 cc 3315 cc 
10% 2543 cc 3292 cc 
20% 2395 cc 3238 cc 
30% 2324 cc 3195 cc 
40% 2424 cc 3142 cc 
50% 2260 cc 3092 cc 
60% 2253 cc 3054 cc 
70% 2323 cc 3019 cc 
80% 2425 cc 3054 cc 
90% 2555 cc 3231 cc 
mean +/- stdev 2409 +/- 121 cc 3163 +/- 106 cc 
variation  5.0% 3.3% 
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6.2.3 Results 
 
Case 1 
The cPTV was assigned as the PTV in this case.  The physical dose received by the 
cPTV and PTV_ref evaluated in 3D and 4D are listed in Table 6.3.  Due to the 
motion effects, the dose distributions over the cPTV of the 4D dose plan were 
different from that shown on the 3D plan especially for the minimum dose.  The 
volume dose histogram of the 3D and 4D dose plans (figure 6.7) reveals the 
minimum dose received by the cPTV was 20.3 Gy and 16.4 Gy and enclosed 26.3 cc 
and 35.5 cc dose volume, respectively (column 2
nd
 , 4
th
 Table 6.3).  As a result of 
4D dose evaluation, the PTV_ref with Dmin of 21.4 Gy indicates that the original 3D 
dose plan using conventional planning technique could be optimized by prescribing 
at the 21.4Gy isodose level to achieve complete coverage of PTV_ref .  This leads 
to reduction of treatment volume by 17%, as the 21.4 Gy enclosed 21.8 cc dose 
volume versus 26.3 cc enclosed by the original planning dose of 20Gy according to 
the 3D dose distribution (column 4 , Table 6.3). Moreover, the maximum dose of 
PTV_ref was reduced by 6.6% (from 24.3Gy to 22.7Gy).  In terms of 4D 
accumulated dose, the new prescription dose volume obtained from the 
re-normalized dose plan was 20.1cc.  And the LDmean was reduced from 1.10 to 
1.03 Gy. 
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Figure 6.7  Radiation dose of 20.3 Gy represents the minimum dose received by the cPTV in 3D dose planning. The 4D dose evaluation 
indicates the actual minimum dose to the cPTV and PTV_ref were 16.4Gy and 21.4 Gy, respectively.  
 
 
 
cPTV: The conventional PTV volume defined according to ICRU 62 
PTV_ref: PTV volume defiend in reference planning CT 
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Table 6.3 Dosimetric comparison between 3D and 4D dose planning for Case 1 
Case 1 Target Dose (Gy) 
Dose volume (cc) 
Lung Dose 
(vol. = 2615 cc)  cPTV (vol. = 19.9 cc) PTV_ref  (vol.=12.6 cc) 
 
 
3D dose 
max  min  mean 
 
24.2  20.3  23.1 
max   min  mean 
 
24.5  21.3   23.3 
VPD      VDmin (V21.4) 
 
26.3      21.8 
max       LDmean 
 
24.2       1.10 
4D dose 24.2  16.4  22.7 24.3  21.4*  23.3 24.9      20.1  
4D dose 
(renormalized dose 
plan - prescribed at 
Dmin)  
22.6  15.3  21.2 
 
22.7  20.0   21.8 
 
    20.1  
 
22.6        1.03 # 
 
cPTV: The conventional PTV volume defined according to ICRU 62 
PTV_ref: PTV volume defined in the reference planning CT 
VPD: Total dose volume encompassed by prescription dose (PD) of 20Gy 
VDmin: Dose volume encompassed by Dmin isodose  
LDmean:  Mean physical lung dose 
*Dmin:  the minimum 4D dose of PTV_ref, which was 21.4 Gy 
# The lung dose was evaluated in 3D (refer to section 8.2.1.3 for calculation) 
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Case 3 
As in case 1, dose plans were generated using the cPTV and PTV_ref as the planning 
target for dosimetric comparison between the conventional and 4D planning 
techniques, respectively.  The same CI value of 1.22 was obtained in both cases. 
According to the results of 4D dose evaluation, the minimum accumulated dose over 
the PTV_ref was 18.7 Gy (figure 7.8b, 7.8c), it enclosed 29.1 cc and 28.0 cc dose 
volume according to the 3D and 4D dose evaluations, respectively (column 4
th
, Table 
6.4).  Hence, by prescribing at the Dmin (18.7Gy) the entire target dose coverage to 
the PTV_ref would be achieved. As compared to the conventional dose plan using 
cPTV as the planning target, of which, 20Gy enclosed 31.2 cc dose volume, the 
prescription dose volume was found to be reduced by 6.7 % (= 29.1 / 31.2).  
However, the maximum dose of PTV_ref was increased by 6.8% (from 23.5Gy to 
25.1 Gy). 
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Figure 6.8  3D and 4D dosimetric comparison on PTV_ref.  Figure 6.8c indicated the PTV_ref (contoured in red) was entirely encompassed by 
Dmin (18.7Gy)   
 
 
A. DVH of 3D dose plan                 B. DVH of 4D dose plan         C. 4D dose distribution — VDmin / 18.7 Gy of PTV_ref  
 
PTV_ref:  PTV volume defiend in reference planning CT 
Dmin:  minimum 4D dose received by PTV_ref 
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Table 6.4  Dosimetric comparison between 3D and 4D dose planning for Case 3  
Case 3 Target Dose (Gy) 
Dose volume (cc) 
Lung Dose 
(vol. = 3049 cc)  cPTV (vol. = 25.6 cc) PTV_ref (vol.= 20.9cc) 
 
 
3D dose  
max   min    mean 
 
23.0   20.0    22.1 
max    min     mean 
 
23.5    20.0     22.4 
V
c
PD     VPD    V18.7Gy 
 
31.2     25.5     29.1 
max         LDmean  
 
23.1          0.94 
4D dose     not calculated 23.5    18.7*    22.3 not calculated      28.0  
4D dose 
(renormalized dose 
plan - prescribed at 
Dmin of PTV_ref)  
 
25.1    20.0     23.8 
 
                 28.0  24.7         1.01 # 
 
cPTV: The conventional PTV volume defined according to ICRU 62 
PTV_ref: PTV volume defiend in reference planning CT 
VPD: Total dose volume encompassed by prescription dose (PD) of 20Gy 
V18.7Gy: Total dose volume encompassed by isodose of 18.7Gy 
LDmean:  Mean physical lung dose 
*18.7:  the minimum 4D dose received by PTV_ref 
# The lung dose was evaluated in 3D (refer to section 8.2.1.3 for calculation) 
V
c
PD : The prescription dose volume (VPD) obtained from the conventional dose plan. 
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CHAPTER 7 
 
BREATH-HOLD VS FREE BREATHING TECHNIQUES FOR LUNG 
CANCER 
 
7.1 Introduction of Deep Inspiration Breath Hold (DIBH) Techniques 
In the past decade, several sophisticated treatment delivery methods such as gating, 
tracking and tumour immobilization with breath-hold have been developed for better 
treatment localization for lung cancer (Hanley et al. 1999; Balter et al. 1998; Barnes 
et al. 2003; Brown et al. 2007).  Various studies (Engelsman et al. 2005; Mageras et 
al. 2004; Berbeco, 2005) have compared the gating and breath-hold techniques and 
these indicate that more margin may be required to allow for the residual tumour 
motion during respiratory gating. The Deep Inspiration Breath Hold (DIBH) 
technique has two distinct features namely deep inspiration, which reduces lung 
density and breath-hold, which immobilizes lung tumours.  The reduction of tumour 
motion using DIBH should permit the field aperture to be reduced for the same target 
coverage.  The lower density of normal lung relative to tumour can further decrease 
the amount of normal lung tissue in the high-dose region, thus reducing morbidity 
and improving the possibility of dose escalation.  Despite the distinctive therapeutic 
advantages of using the DIBH technique, it however may not be compliable to every 
patient, training must be provided prior to treatment.  For patients who are not able 
to comply their unstable or lack of breath-hold control may lead to unsuccessful 
target immobilization and possible treatment failure.  At the Radiation Oncology 
Centre of TMH, the breath-hold and gating concepts were combined.  The tumour 
movement was immobilized using DIBH and the breath hold consistency and 
stability were monitored and controlled by the gating technique.  In such an 
approach the benefits from both techniques are extracted.  The gated-DIBH 
technique for lung cancer radiotherapy has been applied in fifteen cases in TMH 
since 2004.  Since the gated-DIBH dose plan of case P47 (table 3.1) was corrupted, 
the DIBH dose planning evaluation was not applied. The disease characteristic for 
the DIBH group patients can be found in table 3.1. 
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7.2  Clinical Application using Gated-DIBH Technique in TMH 
During treatment, DIBH was conducted using the active breathing coordinator device 
(ABC) (Elekta, Ltd).  The treatment position and the amount of tumour movement 
during breath-hold were controlled according to the abdominal surface tracking using 
the ExacTrac stereotactic positioning system (v.3.5, BrainLab Ltd).  This system 
was developed for automated treatment positioning and is based on optical detection 
utilising IR-reflective markers (figure 7.1).  The theory of the gated-DIBH 
technique is based on the assumption that good tumour immobility relies on the 
consistent performance of breath-hold and this could be confirmed by the geometric 
configuration of the abdomen.  Such hypothesis is in-line with the principle of the 
ExacTrac system in which the 3D configurations are analyzed for performing 
automated positioning.  In addition to the validation of breath-hold stability, the 
ExacTrac system was also applied for the treatment set up.  Considering that the 
setup process was actually performed in a static mode (during breath-hold), the sub 
milli-meter positioning accuracy using the ExacTrac system as reported in the 
literature was therefore expected.  The control of tumour immobility was 
investigated inter- and intra- fractionally.   
 
Figure 7.1 Treatment setup of Gated-DIBH using the ExacTrac stereotactic 
positioning system 
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7.2.1  Treatment Setup using ExacTrac System 
The principle of treatment setup and the applications of the ExaTrac system are well 
documented and the positioning accuracy of within 1 mm for localization of static 
target has been reported 
13 – 15
. The procedure is briefly described here, during the 
treatment, the IR markers were placed onto the positions which had been labeled 
during the CT planning simulation. The markers were tracked on-line with a pair of 
infrared cameras and the three-dimensional (3D) displacement of the markers was 
recorded in a sample rate of 5 Hz. The treatment position was determined by least 
square fit optimization; a matrix was computed on-line to achieve the best mapping 
between the IR markers and the markers recorded on the treatment plan. The 
treatment isocentre was calculated according to the result of mapping and 
consequently aligned with the Linac isocentre (fig. 7.1). The discrepancy between the 
calculated and the planned isocentres was computed in 3D and updated at 0.2 s 
interval. When the breath-hold control was consistent, the positions of the IR markers 
would be the same as those recorded on the treatment plan (ie identical surface 
curvature). However, if breath-hold was unstable, the discrepancy between the 
calculated and planned isocentres will gradually increase. A warning was set for 
discrepancy of greater than 2 mm in any direction, and the treatment would then be 
interrupted manually.  
 
7.2.2  Treatment Margin of the Gated-DIBH Technique  
The margin of the planning target volume (PTV) was evaluated based on 2 factors: 1) 
The treatment setup errors to account for patient setup variation and inter-breath hold 
variation (σs), and 2) the intra-breath hold tumour motion (σt ) in which the residual 
tumour motion during irradiation under breath hold was studied.  From clinical 
evaluations in fourteen patients, the group systematic error and group random error 
of the treatment setup measured at the isocentre were 0.2(R) ± 1.6 mm, 1.0(A ) ± 2.0 
mm, 0.3(S) ± 1.5 mm in the left-right (LR), anterior-posterior (AP) and 
caudal-cranial (CC) directions, respectively.  The PTV margin of individual patients 
(M ptv) was calculated by the quadratic sum of σs and σt.  The group PTV margin 
(GM ptv) was evaluated by the mean of individual’s margins (Mm ) and twice the SD 
of individual margins (Σm ) to cover 95% of the population to receive the prescribed 
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dosage.  The group PTV margins of 3.8 (LR), 4.6 (AP) and 4.8 (CC) mm were 
evaluated and applied clinically.  The clinical implementation of using gated-DIBH 
technique and its efficacy in terms of tumour immobility and treatment set up 
accuracy were reported in the previous study (Wong et al. 2010). The details of 
margin evaluation of for gated-DIBH technique are listed in Appendix II. 
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Table 7.2 Intra -breath-hold tumour motion, individual and group margin. 
Patient 
Intra-breath hold tumour variation σt 
(mm) 
Individual Margin MPTV 
 (mm) 
 
 LR AP CC LR AP CC 
1 0.6 0.3 0.5 3.6 2.5 2.1 
2 0.2 0.3 0.4 0.7 2.7 2.1 
3 0.2 0.2 0.7 0.5 0.7 2.1 
4 0.1 0.2 0.4 0.3 2.3 3.8 
5 0.2 0.3 0.7 1.1 2.1 2.0 
6 0.2 0.3 0.4 2.1 3.6 1.1 
7 0.1 0.5 0.9 0.3 1.4 2.8 
8 0.1 0.3 0.6 2.0 2.2 3.5 
9 0.2 0.3 0.9 0.7 1.3 2.8 
10 0.1 0.1 0.1 0.2 0.3 0.3 
11 0.3 0.5 0.9 1.0 4.7 2.7 
12 0.3 0.1 0.5 3.6 0.4 1.6 
13 0.4 0.5 0.5 2.3 3.1 1.7 
14 0.3 0.2 1.6 0.9 0.7 5.2 
Group 
Mean 
(mm) 
0.2 0.3 0.7 1.4 2.0 2.4 
Group 
SD 
(mm) 
±0.2 ±0.1 ±0.4 ±1.2 ±1.3 ±1.2 
Group Margin (GMPTV) = Mm + 2Σm  (mm) 
3.8 4.6 4.8 
σt: Intra-breath hold tumour variation 
σs: treatment setup error 
Mm: Group mean of individual margins 
Σm: Group std of individual margins 
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7.3   Dosimetric Comparison between Gated-DIBH (3D Dose Planning) and 
Free Breathing (4D Dose Planning) Techniques 
Among the fifteen cases treated with the Gated-DIBH technique, four (cases 1, 3, 4, 
5) were included in this study.  Comparison of dosimetric advantages between 
treatments delivered with DIBH technique based on 3D dose planning and with free 
breathing based on 4D dose planning (ie results presented in Chapter 6) were 
assessed for the four cases.  However, the DIBH dose plan of case 5 was corrupted 
and case 4 with minimal tumour motion, thus only case 1 and case 3 with relatively 
large tumour movement were selected for dosimetric comparison.    
To allow unbiased comparison, equivalent dosimetric properties were verified for 
similarity in dosimetric indices (ie. CI, HI and TCI).  The same dose prescription 
and delivery technique as those applied in the 4D dose study described in Chapter 
6.2.2 (20Gy at the 85% (case 1) and 90% (case 3) isodose level to enclose ≥ 99.5% 
of the PTV volume) was used for the gated-DIBH dose plan.  The GTV was 
delineated on the clinical dose plan using a lung CT window (HU = -500, 1000).  
The Clinical Target Volume (CTV) was defined with a 5 mm margin expanded 
evenly from the GTV to cover the microscopic extent of tumour.  The evaluated 
PTV margins of 3.8 mm, 4.6 mm and 4.8 mm in the LR, AP and CC directions were 
applied.  To eliminate dosimetric variation resulting form discrepancy in dose grid 
between planning systems (BrainScan and CERR), the gated-DIBH dose plan was 
imported into CERR for dose evaluation.  The physical dose received by the PTV, 
GTV and both lungs were assessed.  For consistent dosimetric comparison with the 
4D dose study performed in Chapter 6.2, the terminology was synchronized by 
renaming the GTV, CTV and PTV to GTV_ref, CTV_ref and PTV_ref, respectively..  
 
 
7.3.1 Conversion of Physical Dose to Normalized Dose for Lung Dose Evaluation 
Symptomatic pneumonitis occurs in approximately 0-20% of patients irradiated with 
conventional doses of radiation (Cox et al. 1990; Gross, 1997).  The incidence of 
this side effect appears to be dependent on irradiated lung volume and dose, although 
the exact relationship is not well defined (Lawrence et al, 2010).  In this study, the 
dose was delivered via hypo-fractionation in order to correlate the clinical outcome 
with that of a conventional study.  The physical dose distribution was converted into 
the biologically equivalent dose (BED) distribution (Williams et al. 1985) of 2 Gy 
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per fraction to define the normalized total dose (NTD) distribution.  By using the 
linear quadratic model (Maciejewski, et al. 1986), with an α/β ratio of 3 Gy, the NTD 
for lung was defined by equation (3): 
 
NTD = nd [1+d/( α/β) ]      (3) 
             [1+ 2/(α/β)] 
 
where n is equal to the number of fractions (n=3), d the dose per fraction and α/β for 
the specific end point.  Base on the dose-volume histogram, in which both lungs 
were considered as one organ and the GTV was excluded for dose calculation, the 
normalized mean lung dose (NTDmean) was calculated using equation (4) 
 
NTDmean = Σi νi．NTD i     (4) 
 
Whereνi is the partial lung volume in dose bin i, which received a biological dose 
NTDi.  The percentage of total lung volume receiving NTD ≧20 Gy (VNTD20) and 
NTDmean were assessed and compared between the FB and DIBH groups.  
 
 
7.3.2 Dosimetric Comparison for Treatment Target and Lungs 
Dose planning using the gated-DIBH (section 7.4) and FB techniques (section 6.2.2), 
respectively were compared for case 1 and case 3.  Table 7.3 and Table 7.4 lists the 
radiation doses received by the PTV_ref, GTV_ref and the resultant dose volume 
encompassed by the prescribed dose (20Gy per fraction) planned with the two 
techniques for case 1 and case 3, respectively. The nominal total dose (NTD) of the 
lung volume was also evaluated for assessment of radiation induced pneumonitis. 
Lung dose which was evaluated with the GTV excluded. The FB techniques using 
cPTV and PTV_ref as the planning target, for cases 1 and case 3, respectively were 
discussed in Chapter 6.2, the data of the results was applied here for comparison.  
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Table 7.3  Dosimetry comparison between 3D dose planning with DIBH and 4D dose planning with free breathing for case 1 
CASE   I  
Physical Dose 
(all fractions) 
PTV_ref GTV_ref Lung 
max. 
(Gy) 
min 
(Gy) 
mean 
(Gy) 
VPD 
(CC) 
VPTV_ref. 
(cc) 
max. 
(Gy). 
min 
(Gy) 
mean 
(Gy) 
VGTV_ref 
(cc) 
LDmean  
(Gy) 
Lung volume 
(cc) 
DIBH (3D) 74.0 60.0 70.2 27.9 20.5 73.4 69.2 71.2 1.30 3.72 3210 
FB (4D) 69.7 60.0 65.5 20.1 12.6 67.7 64.0 65.7 1.28 3.3 2409 
NTD 
(all fractions) 
 
Lung  (α/β = 3) 
 NTDmean (Gy3) V20Gy (%) 
DIBH (3D) 17.5 14.3 
FB (4D) 17.5 15.8 
 
DIBH (3D):  3D dose planning using gated-DIBH technique. 
FB (4D):  4D dose planning with treatment performed under free breathing. 
PTV_ref:  PTV volume defiend in reference planning CT      
GTV_ref:  GTV volume defiend in reference planning CT      
VGTV_ref.:  Volume of GTV_ref 
VPTV_ref.:  Volume of PTV_ref 
VPD:  Total dose volume encompassed by prescription dose (PD=20Gy) 
LDmean: Mean physical lung dose         NTDmean: mean nominal total dose 
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Table 7.4  Dosimetry comparison between 3D dose planning with DIBH and 4D dose planning with free breathing for case 3.  
CASE   3 
Physical Dose 
(all fractions) 
PTV_ref GTV_ref Lung 
max. 
(Gy) 
min 
(Gy) 
mean 
(Gy) 
VPD 
(CC) 
VPTV_ref. 
(cc) 
max. 
(Gy). 
min 
(Gy) 
mean 
(Gy) 
VGTV_ref 
(cc) 
LDmean  
(Gy) 
Lung volume 
(cc) 
DIBH (3D) 69.9 60.0 66.6 45.5 37.5 69.3 64.8 67.2 3.92 2.94 5049 
FB (4D) 75.3 60.0 71.4 28.0 20.9 75.0 70.8 72.9 2.92 3.03 3163 
NTD 
(all fractions) 
 
Lung  (α/β = 3) 
 NTDmean (Gy3) VNTD=20Gy (%) 
DIBH (3D) 18.2 19.8  
FB (4D) 17.5 18.2  
 
Abbreviations as in Table 7.3    
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As the results show the target doses were found to be more homogenous using 
DIBH(3D) technique than FB(4D) technique for case 3 and vice versa for case 1.  
This can be explained by the differentiated target volume, as more uniform dose 
distribution tends to be attained for a larger target volume. In case 3, the planning 
target volume employed in the DIBH(3D) dose plan (PTV_ref = 37.5 cc ) was 1.79 
times that of the FB(4D) dose plan (PTV_ref = 20.9 cc).  For case 1, although the 
treatment volumes (cPTV=19.9 cc for FB,  PTV_ref = 20.5 cc for DIBH) of both 
techniques were similar and comparative dose uniformities (max: 74.2 Gy, 73.6 Gy;  
mean: 70.2 Gy, 71.0 Gy for the DIBH and FB dose plans, respectively) were initially 
obtained.  However, after the prescription dose was normalized to Dmin (21.4 Gy) 
by a factor of 1.07 (21.4 Gy / 20 Gy), the maximum and the mean doses were 
dropped to 68.8 Gy and 66.4 Gy, respectively, that certainly improved the dose 
homogeneity.  
 
Although the setup margin of the gated-DIBH technique has been substantially 
reduced compared with the data reported in the literature, still more margin was 
required for the gated-DIBH technique than FB technique as shown in this study. A 
larger irradiated volume (27.9cc, 45.5cc) was obtained using the gated-DIBH 
technique than FB (20.1cc, 28.0cc) in both cases.  The relatively large dose volume 
obtained in the DIBH dose plans was however compensated by the expansion of the 
lungs volume during DIBH, and as a result comparative lung doses were found for 
both techniques in the two cases. In chapter 6, adequate dose coverage to the 
planning target (PTV_ref) has been demonstrated using the 4D planning technique, 
together with the comparative lung doses (NTDmean, VNTD20 ) to that obtained from 
the DIBH studies which had been reported with no symptomatic peumonitis (Ng et al 
2008).  Such results implies that the 4D planning technique proposed in this study 
for clinical application are encouraging.  Dosimetry comparison between disffernt 
treatment techniques as demonstrated in this chapter is recommended to be 
performed clinically for the choice of optimal treatment for individual cases. 
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CHAPTER 8 
 
DISCUSSIONS AND CONCLUSION 
 
8.1   Discussions 
Respiratory motion is a significant challenge in targeting the tumour during radiation 
therapy.  With the availability of 4D imaging, the latest research on 4D treatment 
planning (Birkner et al. 2003; Zhang et al. 2008; Colgan et al. 2008; Wolthaus et al. 
2008) which takes into account the temporal changes in anatomy suggests that this 
could be an optimal technique for treatment of lung cancer.  However, despite its 
appeal, the concept of 4D planning is not yet widely available.  This is because the 
process of 4D planning is rather complex as demonstrated in our study, with the work 
flow containing deformable image registration, automated propagation of target 
delineation and dose transformation between phases and involves 10-20 times more 
processing data than would be required in a standard plan (Rietzel et al. 2005).  
Moreover, validating the accuracy of deformable image registration is difficult due to 
the frequent lack of identifiable physical landmarks.  Several studies (Lin et al. 
2008; Rietzel et al. 2005; Wink et al. 2008)
 
have been published on 4D dose 
calculation using different algorithms of deformable image registration (Chao et al. 
2006; Harten et al. 2002; Thirion, 1998). (eg. voxel-based affine non-rigid image 
registration, optical-flow-based demons registration etc), and the evaluation of DIR 
in clinical studies was generally performed using visual comparison (Chao et al. 
2006; Wink, Chao, et al. 2008)
 
or quantitative comparison (Lin et al. 2008)
 
between 
the morphed and the manual contours.  In our study, the DIR was evaluated 
quantitatively, with the matching indices for lung mapping of around 0.94 – 0.95 
(Table 2.3) which is comparable with previously published results (Lin et al. 2008).  
Since most of the DIR algorithms including IM apply voxel based registration, in 
which the similarity of the voxel intensity is compared, it is therefore imperative to 
employ low-noise 4D CT images obtained from regular breathing in order to achieve 
constructive 4D dose evaluation.  To validate the stability of the 4D-CT images 
employed in our study, the studied cases were screened for the regularity of breathing 
rate.  Moreover, the difference in the GTVs’ volume which had been manually 
contoured in the three phase-specific dose plans (inhale, exhale, 
mean-tumour-position) was studied, the small standard deviations in GTV volumes 
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ranging from 2% to 5% (Table 3.2) suggest that the potential cause of unstable image 
leading to variation in delineated GTV volumes is minimal.  
 
In this study, dose plans performed at different phases were compared for the size of 
iITV volume.  Dosimetric indices such as conformity index (CI), target coverage 
index (TCI) and heterogeneity index (HI) were employed to assess similarities in 
dose distributions among plans for constructive comparisons.  The values of CI 
were found to be lower (better) for cITV than GTV (column 2
nd
, 5
th
, table 5.3), this is 
because CI is a volume dependent factor, which suggests a better CI value is more 
achievable for the larger target volume.  In this study, the CI values of around 1.2 at 
95% target coverage recommended by RTOG 0236 were achieved for all cases 
indicating that optimal dose planning was attained.   
 
As a result of the study, the 4D dose evaluation on the nine clinical cases has given 
us insights into a possible approach to radiation planning where a moving target is 
encountered, these are summarized as follows. 
 
8.1.1  Treatment planning 
It is widely recognized that there are unavoidable positional variation due to tumour 
motion, leading to uncertainties in delivery of radiotherapy for lung cancer.  It is 
difficult to entirely eliminate the potential dosimetric errors caused by these 
uncertainties.  However, a good knowledge of dosimetric effect on tumour motion 
can facilitate selection of optimum treatment technique for individual cases.  The 
treatment planning technique proposed in this study is based on the resultant 
dosimetry by taking into account both geometric and temporal factors, and the 
dosimetric influence of a tumour’s characteristic. 
 
The magnitude of tumour motion is an important factor which contributes 
significantly to under dose coverage of the target, therefore a motion-related 
treatment margin is usually required for treatment planning (Witte et al. 2004; Wu et 
al. 2010; Ng et al. 2008; Rietzel et al 2006; Ekberg et al, 1998).  Several studies 
have suggested that the treatment margin should be derived from the 4D contouring 
or probability distribution of the target positions.  Rietzel et al (2006) used 4DCT to 
characterize tumour motion to define the treatment volume.  Probability based 
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margin was also applied recently.  Ekberg et al (2008) suggested a margin formula 
of 1.64σ (where σ is the combined deviation of tumour motion and treatment setup) 
for nominal probability of 90% in each of the three dimensions.  van Herk et al 
(2000) introduced the margin recipe: 2.5Σ+ 0.7σ’ (Σ: SD of systematic error, σ’: SD 
of random error) to ensure 90% of the patient population would received 95% of the 
prescription dose.  Both formulae were applied regardless of the tumour size.  Our 
results, however, show that the degree of target coverage is associated with both 
factors of displacement magnitude and tumour size; more severe target missing was 
found with a small tumour than with a large one with comparable magnitude of target 
movement.  If only the motion magnitude is considered for margin determination, 
the margin could be over-estimated for the case of large sized target.  Such a finding 
can be deduced from the data shown on table 5.1.  The minimum target coverage of 
73.0% and 95.87% was found with cases 3 and 7 both with tumour movement of 
about 4 mm but with tumour size of 3.0 cc and 12.8 cc, respectively.  The 95.7% 
target coverage obtained in case 7 demonstrating the goals of target coverage 
assigned by the two formulae had been fulfilled even before any margin was applied.  
This implies that if motion magnitude only is considered for margin determination, 
this would result in excessive treatment volume.  
 
Although, dose planning performed at the temporal mean tumour position has been 
well demonstrated for dose coverage maximization (Engelsman et al. 2001; Witte et 
al 2004; Colgan et al. 2008), and substantiated by the results of this study (treatment 
volumes were shown to be optimized with iITVmean, see table 5.2).  It is however 
noteworthy that the degree of maximizations is governed by the characteristics of the 
motion of the tumour.  For instance, if the target travels in a sinusoidal-like 
trajectory during the respiratory cycle, the maximization of target coverage would be 
limited.  This is because full target irradiation is obtained only over a fraction of the 
respiration cycle (figure 5.3), no additional gain would be obtained even with the 
temporal-mean dose-plan.  On the other hand, for cases with flat-top sinusoidal 
trajectory, the tumour stayed near the end-exhale position for most of the respiration 
cycle which corresponds to the position of temporal mean.  Hence, the 
temporal-mean dose plan is more advantageous for cases with such a tumour 
movement trajectory.  In these cases, the treatment volume would be substantially 
reduced using iITVmean compared to cITV.    Such findings demonstrate the 
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limitation of the classical ITV in regard to excessive normal tissue irradiation since it 
is defined only from geometrical aspect without accounting for the temporal nature 
of the tumour motion.  Nevertheless, to delineate the mean target position is a 
challenge and image-guided positioning may be necessary to implement the desired 
treatment.  For cases with targets having sinusoidal-like trajectories dose planning 
at the exhale phase is recommended for minimizing the setup uncertainty as no 
substantial benefit is gained by using the temporal mean dose plan.  Moreover using 
cITV as the planning target, treatment volume could be optimized with the excessive 
target irradiation during its oscillation along the high-dose-region within the beam 
aperture (table 6.1).   
 
Numerous studies (Hurkmans et al. 2001; Erridge et al. 2003) have described the 
effect of respiration motion on the shape of dose distribution by blurring the planned 
dose with a Gaussian distribution.  Similar to our study, Wolthaus et al (2008) 
evaluated the treatment margin from GTV to PTV (CTV was not applied) based on 
the internal target volume, however dose-probability-based margin recipe (van Herk 
et al 2000, 2003, 2004; Witt et al 2004) was applied for the evaluation.   In their 
study, with the provision of on-line correction, the systematic errors contributed from 
setup and respiration was negligible, and only the random errors and the penumbra 
width of dose distribution were accounted for margin calculation.  Their results 
showed that the total treatment margin of less than one third of the peak-to-peak 
amplitude of tumour motion was suggested for the typical respiration motion of up to 
1.5 cm amplitude.  To compare their results with this study, the suggested 
one-third-amplitude margin was applied using the data of this study to hypothetically 
evaluate the total treatment volume.  The calculation for the treatment volume based 
on van Herk et al’ s study (2000, 2004) and the deduced dose volume is described in 
Figure 8.1.  As shown by the results, the planning target volume defined by iITV 
which provided 100% prescription dose coverage was only 3.5% in average (range: 
-19.2% – 19.5%) larger than the deduced dose volume defined using 
probability-based margin recipe of which the 95% prescription dose coverage was 
aimed (Table 8.1).  The relatively large CI (CI=1.67) applied in case 3 indicates the 
planning target was irregular in shape, and the result of comparative large 
probability-based planning among all cases leading to a question whether the iITV 
defined in 4D basis would be more favorable to the irregular shaped target, such 
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presumption requires more data to confirm.    Our preliminary findings however 
suggest that iITV provided good target coverage compared to that using 
probability-based margin recipe in terms of volume and coverage specificity.  Such 
encouraging results could be due to iITV accounting for the non-rigid anatomical 
displacement on the dose distribution during breathing (both temporal and spatial 
factors are considered), whereas only spatial factor is considered for the static dose 
convolution with translational displacement probability.  4D dose planning using 
DIR and dose convolution with PDF for determination of treatment volume are 
increasingly applicable.  A thorough evaluation to determine the effectiveness of 
both techniques, in terms of treatment volume optimization and target coverage 
specificity, would be practically useful.  Since probability-based margin is evaluated 
based on patient statistic, further investigation is not possible at the present stage due 
to insufficient patient data.  
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Figure 8.1 According to van Herk et al’s study (2000, 2004), with the tumour position well defined during treatment, the volume of PTV(VpTV) 
provided a minimum dose of 95% to the tumour (ie GTV) could be defined by expanding the tumour with a SD of respiration motion. The SD of 
respiration motion was determined by one-third of peak-to-peak amplitude of tumour motion. The equivalent diameter of GTV was calculated by 
assuming the GTV was in spherical shape and the VPTV was derived in oval volume using Equation (5). The V’PTV denotes the planning dose 
volume of the PTV, derived by multiplying the VPTV with the conformity index (CI listed in Table 4.3).  
 
 
 
 
 
V pTV =  4/3 Π x (SD LAT + Req) x (SD AP + Req) x(SD cc + Req)    ( 5 ) 
V’PTV =   V PTV x CI 
 
 
 
         SDLAT : SD of respiration motion in lateral direction 
         SDAP:      SD of respiration motion in anterio-posterior direction 
         SDCC:      SD of respiration motion in cranial-caudal direction 
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 Table 8.1. Treatment volume comparison between V’pTV and iITV. The volumes of iITV were larger than V’pTV by an average of 4.4%. 
Case GTV  
(cc) 
Req 
 (mm) 
Displacement (pk – pk) 
(mm) 
SD of Respiration motion 
(mm) 
VPTV 
(cc) 
V’PTV (VPTV x CI) 
(cc) 
iITV 
(cc) 
iITVmean - V’PTV 
( % difference ) 
   LAT AP CC SDLAT SDAP SDCC     
1 1.42 6.9 5.8 1.6 0.3 1.9 0.5 0.1 2.0 2.0 x 1.53 = 3.1 3.7* + 19.5 
2 1.93 7.7 0.5 2.6 3.5 0.2 0.9 1.2 2.5 2.5 x 1.57 = 3.9 4.0# + 2.5 
3 3.0 8.9 0.5 2.6 3.0 0.2 0.9 1.0 3.7 3.7 x 1.67 = 6.2 5.2# -19.2  
4 6.74 11.7 1.1 0.5 0.0 0.4 0.2 0.0 7.0 7.0 x 1.58 = 11.1 11.1# 0 
5 4.06 9.9 1.1 3.2 3.0 0.4 1.1 1.0 5.1 5.1 x 1.39 = 7.1 7.3# + 2.7 
6 17.89 16.2 2.1 1.6 6.0 0.7 0.5 2.0 21.6 21.6 x 1.15 = 24.8 26.8# + 7.5 
7 12.8 14.5 1.5 3.5 0.0 0.5 1.2 0.0 14.3 14.3 x 1.39 = 19.9 23.9# + 15.7 
8 5.5 11.0 1.5 1.5 9.0 0.5 0.5 3.0 7.7 7.7 x 1.63 = 12.6 14.2# + 11.2 
9 12.4 14.4 2.4 8.3 9.2 0.8 2.8 3.1 18.9 18.9 x 1.42 = 26.8 23.8* -3.0 
Average +3.5 
# iITVmean was used, data was extracted from Table 6.1 
* iITVall was used, data was extracted from Table 6.1 
SDLAT:  1/3 x LAT (peak-to-peak motion amplitude in lateral direction) 
SDAP:  1/3 x AP (peak-to-peak motion amplitude in anterio-posterior direction) 
SDCC:  1/3 x CC (peak-to-peak motion amplitude in cranio-caudal direction) 
Req: equivalent radius of GTV
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8.1.2 Concerns for Radio-Biological Dose Influence  
The possible influence of the biological effect on dose distribution of a moving target 
was not within the scope of this study.  However, the recent study carried out by van 
Herk et al (2003) indicates that the biologic fractionation effect on dose distribution 
for the concerns of additional margin is negligible.  In their study, the physical and 
biologic fractionation effects of random geometric errors and respiration motions 
were assessed; the resulting dose distributions were compared using Gaussian 
blurring with the planned dose.  Due to the non-linear relationship between the 
physical dose and BED, the total dose distribution was slightly wider; with 0.2 mm 
for α/β ratio of 3Gy. The widening was reduced with α/β ratio and increased with 
random error of more than 1 cm motion amplitude.  Moreover, they concluded that 
there was no additional margin requirement due to the biologic effect of fractionation, 
as errors that shift the target towards higher dose levels completely cancel the effect 
of errors that shift the dose toward lower levels. Hence, the proposed planning 
volume for performance of hypofractionated treatment should be entirely safe.  
Nevertheless, a more detailed analysis of the biological effect of random and 
systematic errors by van Herk et al (2002) pointed out that the effect of insufficient 
geometrical margin can lead to significant lost of Tumour Control Probabily (TCP). 
In their study, a threshold margin was defined, below which, the TCP of the 
population will start to decrease sharply. It is therefore important to verify the 
evaluated treatment margin carefully before clinical implementation.    
 
In this study, the 4D dose planning deduced from the concept of iITV has been 
demonstrated to be effective for optimizing dose coverage of a moving target.  
However, complications such as radiation-induced puemonitis may limit the clinical 
application of the technique.  The lung doses evaluated in the 4D dose plans were 
found comparable with that using gated-DIBH techniques.  Although there is no 
evidence of a dosimetric threshold level for inducing symptomatic pneumonitis, 
VNTD20 limited to ≤30-35% and NTDmean, to ≤20-35Gy were suggested by 
QUANTEC (Lawrence et al, 2010) to lower the risk level of radiation-induced 
puemonitis to within 20% of the treated patients. Such criteria were well achieved in 
the 4D dose planning study (NTDmean was 17.5 Gy andVNTD20 ranged from 16% to 
18 %, for both cases).  Although only two cases were selected for the assessment, 
the relatively acceptable lung dose values obtained in both cases indicate that the 
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proposed 4D planning technique are encouraging.   
 
Since the resultant dosimetry can be complex under different circumstances; for 
instance the volumes of lung and tumour, the nature of tumour motion, the planning 
phases, the selected planning target volume, etc, which have been discussed in the 
study, performing the various planning techniques are advised and the choice of 
treatment technqiue should be based upon the adequate target coverage and the result 
of lung dose evaluation to account for the probability complication.  If similar 
dosimetry is obtained with both FB and gated-DIBH techniques, FB treatment with 
4D planning technique would have an implementation advantage over the DIBH 
technique.   
 
8.1.3 Future Studies 
8.1.3.1 Treatment Implementation 
In this study, the possibility of 4D dose planning offers a solution on how to 
maximize the planning dose to the target volume by revealing the dynamic dose 
distribution in the presence of motion.  Our results demonstrate that iITV reduces 
the dose volume in all cases compared with that derived from the classical technique 
(Table 5.2).  The discrepancy in geometric coverage between the iITV and cITV 
implies that treatment margin to cover the entire range of tumour motion is not 
necessary.  Nevertheless, the concept of iITV has not yet considered the variation in 
tumour motion, which may occur between simulation and treatment caused by 
unstable breathing.  The accuracy of the delivered dose using iITV for clinical 
application could however be assessed according to the concept suggested in 
Seppenwoolde et al’s study (2007), in which the dosimetric uncertainties due to 
breathing motion was simulated.  In this study, the 4D dose of each voxel in the 
different phases was stored in the corresponding order by TDx (see figure 2.4), based 
on the assumption of consistent correlation between the internal and external 
movement as obtained during CT planning simulation, the resultant 4D doses over 
the target volume during treatment can be estimated on-line or off-line with provision 
of real-time respiratory surrogate data.  The concept of on-line 4D dose evaluation 
is presented in Appendix III.  In common with other respiratory gating or tracking 
techniques, the treatment technique proposed in this study also require stable 
breathing of the patient during treatment, however the total dose received by the 
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patient could be estimated at any time during or after treatment. The technique of 4D 
dose evaluation in real time using the tool-box would be investigated following this 
study.  
 
8.1.3.2 Application  
A tool box written in MATLAB in conjunction with CERR was developed for 4D 
dose calculation in this study.  The 4D dose Tool Box allows the 3D treatment dose 
plans, generated either commercially or in-house developed treatment planning 
system, with planning data contained in DICOM-RT format, to process 4D dose 
calculation using deformable dose registration approach.  However, the algorithm of 
the tool box is restricted to the DICOM image format in grid resolution of 1.0-1.01 
mm and slice thickness of 3 mm.  Moreover, the processing time of 4D dose 
calculation depends on the size of the target volume and the resolution of the dose 
grid.  The study was performed with a computer with 4GB of RAM and 2.5 GHz 
processor speed.  For instance, to work out the 4D dose distribution of a cubic 
volume of 2 cm in dimension, the processing time was approximately 48 hours for 
the dose grid of 1 mm.  The processing time and the application flexibility of the 
tool box can be improved by modifying the 4D dose calculation algorithm, which 
will be performed after this study.    
 
8.1.3.3 Limitations 
The study relies on good quality 4D CT images for effectual dynamic image 
registration and therefore patients with regular and stable breathing is a pre-requisite 
in order to perform low-noise image reconstruction.  The technique is therefore 
restricted to the cases where stable breathing is achieved or breath coaching is 
effective.  In this study, the 4D dosimetry was evaluated based on DIR and although 
the accuracy of IM has been validated by good contour matching, absolute 
registration accuracy based on point to point correspondence may be needed to 
further ensure the robustness of the technique. 
 
Numerous studies have reported the limitation of PB algorithm in heterogeneous 
media (Krieger et al. 2004, Nisbet et al. 2004, Irvine et al. 2004, Ahnesjo et al. 1999). 
This is because the PB algorithm uses a one-dimensional path density correction 
which does not model the distribution of secondary electron in the media. Doses are 
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calculated according to the radiological depth along a ray line from the radiation 
source to the calculation point, and does not account for the effect of side and 
backscattered radiation. Krieger et al (2004) evaluated the accuracy of dose predicted 
in heterogeneous media by a PB, a collapsed cone (CC) and a Monte Carlo (MC ) 
algorithm, using a simple phantom consisted of Styrofoam and white polystyrene. 
Doses were measured in the central layer of white polystyrene. It was found that, in 
white polystyrene, both MC and CC calculations agreed satisfactorily with the 
measurements whereas the PB algorithm calculated 12% higher doses on average.  
Nisbet et al (2005) studied the dosimetric accuracy of the CC algorithm based on 
phantom study and obtained good agreement between measured and calculated dose 
to within 2%, for most of the homogeneous and heterogeneous cases. Their study 
suggested that CC algorithm was preferable to PB algorithm despite the fact that 
there may still be some discrepancy between calculation and measurements. The 
possible errors with CC algorithm are discussed in recent studies where the published 
results are mainly governed by the particular phantom geometry and set-up (Klein et 
al 1993, Sauer 1995). In this study, the PB algorithm was applied for relative dose 
comparison, however for absolute 4D dose evaluation the gold standard of MC 
algorithm or CC algorithm is used. 
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8.2  CONCLUSION 
The uncertainty in target coverage arising from the motion effects has been a major 
obstacle in applying escalated dose treatment for better therapeutic gain, as excessive 
irradiation is often traded for the possible marginal miss.  In this study, a new 
concept of internal target volume, namely iITV, was defined from the 4D dosimetry.  
The iITV precisely identifies the required treatment volume and offers the adequate 
dosimetric coverage for the dynamic target (tumour).  The proposed 4D planning 
techniques based on the iITV approach has proved to be useful for significant 
reduction of the irradiated volume without compromising the target coverage.  
However, the accumulated dose distribution of 4D radiotherapy is dynamically 
complex and the control factors such as tumour size, magnitude of tumour 
displacement, tumour motion characteristic and the reference phases for dose 
planning etc., are interactively affecting the resultant dose distribution.  Hence there 
are no definite solutions to the treatment or planning techniques for 4D radiotherapy 
such as those applied in 3D radiation treatment; for example, better dose conformity 
dynamic conformal radiation techniques (eg. intensity modulation radiation therapy 
(IMRT), volumetric modulation arc therapy (VMAT)) would be preferred to static 
conformal radiation.  As demonstrated in the study, the reference dose plan 
performed at the temporal mean tumour position does not necessarily provide the 
optimal dose plan since the resultant dose distribution depends on the motion nature 
of the tunour.  Moreover, the geometric-defined treatment margin could over 
emphasize the required treatment volume for actual target coverage, consequently 
leading to potential restriction in dose escalation by the excessive irradiation.   
 
In this study, a DICOM-RT based toolbox was developed to enable 4D dose 
calculation based on deformable image registration.  The toolbox provides an user 
friendly platform for 4D dose calculation.  Once the compatible DICOM-RT data is 
input, the 4D dose distribution over the treatment regions is automatically computed 
and the results are presented and analyzed schematically (eg. 3D dose distribution 
map, accumulated and differential volume dose histogram, etc).  Upon the choice of 
adequate dosimetry, the most suitable and optimal treatment modalities and planning 
techniques can be determined for an individual case.  
 
Apart from using DIR, a modeling technique which based on the convolution of the 
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static dose distribution with the probability distribution function (PDF) of the organ 
motion was also applied for 4D-dose planning recently.  As the result of comparison 
between the two techniques, though the application of iITV are encouraged, however 
due to the lack of sufficient clinical data, the results and course are prelimarily and 
further investigations are required.  
 
Despite the technology for 4D imaging and dose calculation is becoming 
increasingly available but 4D planning and delivery are still in their initial phase of 
research and development.  This study demonstrates a novel 4D dose planning 
platform which not only offers realistic treatment dosage analysis, but also facilitates 
optimal dose plan by minimizing the treatment volume.   
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APPENDIX I 
A1.1  A program code for DE_DOSE_REG  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%  DE_DOSE_REG %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%   A code to register the pixel dose at each breathing phase corresponding to the IM order                          %%% 
%%   [sort_morphdata] contains image morphing data in 1 mm resolution                                                      %%% 
%%   [fullsetdose_done] contains dose data in 1 mm resolution                                                                  %%% 
%%   [index_dose] stored doses in the order corresponding to target source coordinates                                  %%% 
%%   save full set of dose in the file name of “completedose_x” for xth phase                                            %%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
 
for i = 1 : size(fullsetdose_done) 
    if sort_morphdata(1, 1:3)== fullsetdose_done(i, 1:3) 
        p = i  
    end; 
end; 
for w = 1 : size(sort_morphdata) 
for m = p : size(fullsetdose_done) 
if sort_morphdata (w, 1:3) == fullsetdose_done(m, 1:3) 
index_dose(sort_morphdata(w,7))= fullsetdose_done(m,4); 
p = p+1; 
end; 
end; 
end; 
t2 = clock; 
etime(t2, t1) 
save completedose_x 
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A1.2  A program code for ADD_ALL_DOSE 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%   ADD_ALL_DOSE %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%   
%%    A code to attain time-weighted dose summation of TDx                                                 %%%%%%%%%%%%%%%%%%%%%                                
%%      The accumulated dose over a breathing cycle = Index_dose1 + Index_dose2 + … Index_dose10  %%%%%%%%%%%%%%%%%%%%%                                  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
load completedose_0.mat 
Buffer_index_dose = index_dose*0.1; 
clear index_dose; 
load completedose_10.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_20.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_30.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose 
load completedose_40.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_50.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_60.mat 
Buffer_index_dose = index_dose*0.1+ Buffer_index_dose; 
clear index_dose; 
load completedose_70.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_80.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
clear index_dose; 
load completedose_90.mat 
Buffer_index_dose = index_dose*0.1 + Buffer_index_dose; 
index_dose = Buffer_index_dose; 
save completedose_all  
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APPENDIX II 
 
A2  TREATMENT MARGIN VERIFICATIONS FOR THE GATED-DIBH 
TREATMENT 
 
A2.1  Treatment Setup error (σs) 
Treatment setup error (σs) which accounts for patient setup variation and 
inter-breath-hold variation was evaluated prior to the first treatment.  This was 
verified in the treatment room by simulating the entire set up procedure.  The 
stereotactic couch tray was placed on the top of the treatment couch; patient lied on 
the tray with the same posture as during the CT scan.  Breath-hold was repeated 
several times to ensure the consistency of the positioning.  Data were recorded 
throughout the whole procedure by the ExacTrac.  Once the treatment isocentre was 
confirmed, it was marked on the patient according to the LINAC lasers.  The patient 
was then transferred to CT for isocentre displacement verification.  To avoid any 
skin movement which may displace the skin marks, the patient was instructed to 
maintain in the same posture and was carefully transferred together with the 
stereotactic couch tray to the CT for displacement verification.  The CT was located 
approximately 10 meters away from the treatment room.  To identify the isocentre 
position on the CT image, three radio-opaque markers were attached on the skin 
marks of the patient, two on the lateral and the third on the anterior part.  A CT scan 
was performed with breath-hold with a slice thickness of 3 mm and the central slice 
positioned at the isocentre plane.  To assess the amount of isocentre shift, the 
verified CTs were fused with the treatment plan using the tumour as a reference.  
The treatment setup error σs was determined from the displacement between the 
planning and the treatment isocentres indicated by the radio-opaque markers.  The 
systematic setup error for the group (Ms) is given by the mean of individual errors, 
and the group random set up error (Σs ) by the standard deviation (SD) of individual 
errors. 
 
The treatment setup error was assessed prior to the first fraction of the treatment.  
The displacements at the isocentre of individual patients are listed in Table A2.1.  
The ranges of displacement were -2 – 3.5 mm, -1.7 – 3.6 mm and -2.7 – 4.4 mm in 
the direction of LR, AP and CC, respectively.  The group systematic errors Ms of 
0.2 (LR), 1.0 (AP) and 0.3 (CC) suggest that the setup errors in the preparation 
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processes (eg. the setup error on the CT scanner, the offset error of laser alignment, 
etc.) were small.  On the other hand, the group random errors Σs of ±1.6 (LR), ±2.0 
(AP), ±1.5 (CC), indicate the discrepancy in tumour immobility among individuals. 
 
Table A2.1 The inter-fractional treatment setup displacement (σs) measured at the 
isocentre in the left-right (LR), anterio-posterior (AP) and cranio-caudal (CC) 
directions of all cases. 
Patient 
Treatment setup error σs (mm) 
LR AP CC 
1 3.0 -2.3 1.5 
2 0.1 2.6 -1.7 
3 0 0 0 
4  0 -2.2 3.6 
5  -1 2 0 
6 -2 3.5 0 
7  0 0 0 
8  -2 2 3 
9 0 1 0 
10  0 0 0 
11  -0.2 4.4 0.2 
12  3.5 0.1 -0.3 
13  2 2.8 0.3 
14  0 0 -2 
Group systematic error (Ms ) 0.2 1.0 0.3 
Group Random error (Σs ) ±1.6 ±2.0 ±1.5 
 
 
A2.2  Intra-breath-hold tumour motion evaluation  
Despite of the numerous debates on correlation between internal and external 
movement (Koch et al, 2004, Hoisak et al 2004, Ahn et al 2004), the surface 
movement was stringently restricted in attempt to strive for the minimum tumour 
motion.  In 2006, Stock et al (2006) decisively demonstrated the correlation between 
tumour and external markers movement on 16 lung/liver cancer patients.  In their 
study, the movements during several respiratory cycles in 1) stable breathing, 2) 
DIBH and 3) deep expiration breath-hold were investigated using a multi-slice CT 
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scan in the dynamic 3D scan mode (fixed table position) every 3s, with the total scan 
volume of 24 mm length.  Good tumour – marker correlation was reported with the 
tracking marker placed above tumour or at the xiphoid process; the mean Pearson 
correlation coefficient was reported of 0.83±0.17 (0.77 – 0.89).    
 
A2.2.1 Tumour – marker correlation study 
In the study of DIBH technique, the relationship between tumour movement and 
external marker movement during DIBH was assessed retrospectively.  The tracking 
marker was selected according to Stock et al’s method.  It was primarily selected 
with the marker located close to the tumour, for the case with all the markers 
positioned far from the tumour, the marker near to the xiphoid process was selected. 
The relative movement between the tracking marker and the tumour was determined 
from their positions on the two sets of planning CT images.  Since the patient was 
kept in the same position during the two CT scans, the stereotactic tray was 
considered integrated with the patient, the fiducial markers which embedded at the 
bottom of the stereotactic tray was applied as a measurement reference for the tumour 
and marker movement.  Since the set of fiduical markers consists of 3 columns, 
which laid in a pattern of “N” along the cranial-caudal direction, of which the fiduical 
markers located at the middle column can be found as a single spot on the axial view 
and travelling along the lateral direction while slicing through the CT set.  A specific 
fiducial marker shown on the axial CT was selected and identified from both CT sets 
by the same distance measured from the fixed markers located at the left or right 
column and used as a reference point (P) for measurement (fig.A2.1a).  The 
tumour – marker correlation was evaluated by comparing the differences in tumour 
movement (∆T) and the tracking marker movement (∆TM) between the 2 planning 
CT sets in x (left-right), y (anterior – posterior) and z(caudal- cranial) directions.  
The ∆T and ∆TM were defined in all 3 directions as follows:  
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where T, TM denotes the tumour and tracking marker positions, respectively.  The 
subscript “1” and “2” indicate data acquired from CT1 and CT2, respectively.  The 
details of measurement are depicted in figure A2.1.  To improve the measurement 
accuracy, the variations in GTVs delineation between the two CT sets must be 
minimized as this could affect the localization of the tumour centroid.  This can be 
achieved if the two GTVs are accurately aligned since the centroid of the GTVs 
would coincide on the aligned CTs.  Accurate alignment of the GTVs was achieved 
in the study by using intensity based image fusion.  In assumption of no distortion 
on the GTV volume, based on maximum intensity similarity in voxel based 
comparison, image registration was performed using rigid transformation (image was 
aligned with one to the other with translational and rotational adjustments).  As a 
result, the T1 and T2 would be the same, and with varied TM and P between the two 
CT sets if the tumour position was not the same.  Moreover, in order to improve the 
measurement spatial resolution, in the case where the centre of the tracking marker or 
the point P did not appear on the CT image, interpolation between neighboring slices 
was performed.  The centre of the TM was traced by the size of TM measured on the 
consecutive CTs and interpolated based on the 2
nd
 order polynomial correlation as 
demonstrated in figure A2.1c  
  112 
Figure A2.1 Two planning CT scans performed with DIBH were fused with 
reference to GTV; the different sizes of TM indicate position discrepancy of GTV. 
The reference point P (in circle) of measurement was selected at the isocenter slice, 
which was identified on two CT sets by the same distance measured from the fixed 
fiducial marker (right). The center of TM was interpolated according to the size of 
TM measured on (b) the consecutive CT images using the (c) second order 
polynomial fit. The TM’s center lied at Z =152.3 mm in above case. 
 
 
(a) 
 
(b) 
 
(c) 
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∆T was plotted against ∆TM and the degree of correlation was assessed using linear 
least squares fit and the Pearson product-moment correlation coefficient (R
2 
) as 
shown in equation A3 where (β1) is the gradient and (β2) the intercept   
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The relationship between the tumour movement and the tracking marker movement 
during breath-hold is demonstrated in figure A2.2. Values of R
2
 of 0.81, 0.76 and 0.85 
obtained in LR, AP and CC directions, respectively suggest a linear correlation as 
reported by Stock et al. The values of β1 being 0.61 (LR), 0.46(AP) and 0.87(CC), 
were all less than unity indicating that the magnitude of tumour movement were 
generally less than the marker movement during breath-hold. The β2 (range: 0.06 – 
0.28) are closed to zero in all directions. 
 
Figure A2.2. Tumour-marker correlation in LR, AP, and CC directions based on the 
linear least square fit evaluation was shown in Figs. A2.2(a) – (c), respectively. 
The Pearson correlation coefficient (R2) expressed the degree of linearity. 
The characteristic of the linear relationship can be derived from the slope 
and the intercept of the equation. 
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A2.2.2  Intra-breath-hold motion 
Since intra-breath hold tumour motion could be caused by the quiet excursion of 
abdominal diaphragm or unsteady breath-hold.  Such motion will introduce an extra 
treatment variation in addition to the previously defined set up error.  The 
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intra-breath-hold tumour movement, which was constrained with a pre-defined 
tolerance (< 2mm at isocentre as estimated with ExacTrac), varied around its mean 
position, and in a standard normal distribution.  The range of variations of the 
tumour motion was defined by the standard deviation of the tumour movement (σt ), 
which was interpreted by the tracking marker movement.  The standard deviation of 
tracking marker movement is defined (σTM ) as follow:   
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The evaluation was applied with data recorded in the process of treatment set up 
verification.  Where n is the total number of sample data of the recorded tracking 
marker positions of all successful breath holds.   is the position of the jth 
sample,  is the mean position of the tracking marker calculated from all successful 
breath-holds.  
 
The standard deviation of the intra-breath-hold tumour motion σt was determined by 
combining equation (A3) and (A4).  It is also assumed that β2 is close to zero and 
can therefore be ignored.  Derivation of the resulting equation (A5) had been 
depicted in the Wong et al’s study (2010) . 
 


























iii
t T M1
      (A5) 
 
The amount of intra-breath-hold tumour movement was evaluated by the marker 
movement weighted by the slope of regression β1 as suggested in equation A5.  The 
intra-breath-hold tumour movements in all three directions were found to be small 
compared to σs (column 6
th
 – 8th , Table A2.2). 
 
PTV Margin Estimation 
In 1993, the international Commission on Radiation Units and Measurements (ICRU 
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50) published definitions for target volume for photon radiotherapy. The gross 
tumour volume is the confirmed tumour that is palpable or visible by physical or 
radiological examination. The clinical target volume is the GTV plus a margin for 
sub-clincial disease.  The PTV is the CTV plus a margin to allow for geometrical 
uncertainty in its shape and variations in its location relative to the radiation beams 
due to organ mobility, organ deformation, and patient setup variation.  In our study, 
both of the inter- and intra-fractional organ mobility were taken into account for 
margin evaluation.  However, since the treatment setup was performed under 
breath-hold, the inter-fractional organ mobility and setup variation were genuinely 
integrated during evaluations.  The tumour deformation was not studied as it was 
assumed to be consistent under stable DIBH control and can be ignored during the 
intra-fractional tumour motion.  The PTV margin of individual (M ptv) was defined 
by 2 factors: 1) the treatment setup error σs and 2) the variation of intra-breath-hold 
tumour motion σt.  Assuming that the tumour oscillates around a mean position 
during breath-hold, the range of intra-breath-hold movement was partially 
overlapped with the range of movement defined by σs. σs and σt were therefore 
considered not to be linearly related.  M ptv was calculated by the quadratic sum of 
the 2 factors as follow: 
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Three standard deviations σt was used to include the 99.9% of the tumour movement.  
Despite of the small sampling group, the group PTV margin (GM ptv) was evaluated 
by the mean of individual’s margins (Mm ) and twice the standard deviation of 
individual margins (Σm ) to cover 95% of the population to receive the prescribed 
dosage.  
 
GM ptv  = Mm  + 2 Σm       (A7) 
 
 
The evaluated group PTV margin (GM ptv) of the study were listed in Table A2.2. 
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TABLE A2.2 The Intra-breath hold tumour motion was derived from the movement of the tracking marker. The position of tracking marker w.r.t. the tumour 
is listed in column 2. The standard deviations (SDs) of tracking marker movement (σTM) in 3D are depicted in 3rd – 5th. The tumour movement was 
interpreted according to tumour-marker correlation and the SDs of tumour motion (σt ) in 3D were evaluated based on equation 5 and the results are listed in 
6
th
 – 8th.  PTV margin of individual (MPTV) and of group margin (GM ptv) in 3D are listed in column 9
th
 – 11th . 
Patient Tracking 
marker 
from 
tumour 
(cm)  
Intra-breath hold tracking 
marker variation 
±σTM 
(mm) 
Correlated Intra-breath 
hold tumour  
variation 
±σt 
(mm) 
 
Individual Margin  
(MPTV) 
 
(mm) 
  LR AP CC LR AP CC LR AP CC 
1 2  1.0 0.7 0.6 0.6 0.3 0.5 3.6 2.5 2.1 
2  0.3 0.4 0.6 0.4 0.2 0.3 0.4 0.7 2.7 2.1 
3  Xiphoid 0.3 0.5 0.8 0.2 0.2 0.7 0.5 0.7 2.1 
4  0.6  0.2 0.5 0.4 0.1 0.2 0.4 0.3 2.3 3.8 
5  0.3  0.3 0.6 0.8 0.2 0.3 0.7 1.1 2.1 2.0 
6  1.5 0.3 0.7 0.4 0.2 0.3 0.4 2.1 3.6 1.1 
7 0.3 0.2 1.0 1.1 0.1 0.5 0.9 0.3 1.4 2.8 
8  0.3 0.2 0.6 0.7 0.1 0.3 0.6 2.0 2.2 3.5 
9 0  0.4 0.6 1.1 0.2 0.3 0.9 0.7 1.3 2.8 
10  Xiphoid 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.3 0.3 
11  1 0.5 1.2 1.0 0.3 0.5 0.9 1.0 4.7 2.7 
12  0.3  0.5 0.3 0.6 0.3 0.1 0.5 3.6 0.4 1.6 
13  1.5  0.7 1.0 0.6 0.4 0.5 0.5 2.3 3.1 1.7 
14  4  0.5 0.5 1.9 0.3 0.2 1.6 0.9 0.7 5.2 
Group Mean (mm)   0.4 0.6 0.8 0.2 0.3 0.7 1.4 2.0 2.4 
Group SD (mm)  ±0.3 ±0.3 ±0.4 ±0.2 ±0.1 ±0.4 ±1.2 ±1.3 ±1.2 
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Group Margin (GMPTV) = Mm + 2Σm  (mm) 3.8 4.6 4.8 
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APPENDIX III 
 
The variation in tumour motion which may occur between simulation and treatment 
caused by unstable breathing is not accounted for in the 4D dose planning technique 
proposed in the study.  Based on the assumption of consistent correlation between 
the internal (tumour) and external movement (marker placed on the xiphoid) during 
simulation and treatment, the amount of delivered dose could be estimated on-line or 
off-line according to the breathing pattern.  Figure A2 below shows the variations of 
the breathing pattern acquired during CT simulation and treatment.  Since the 4D 
dose was calculated by summation of TDx which defines the 4D dose received by the 
planning target at the xth breathing phases, the 4D dose received during treatment 
could be estimated from the TDx used in the dose planning according to the 
amplitude of the breathing.  TDx can be extrapolated for the breathing amplitude 
that are larger than that used for the planning CT,    
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Figure A1 demonstrates the insignificant dose variations caused by unstable 
breathing between CT simulation and treatment, using case 3 as an example. Due to 
the flat top sinusoidal tumour movement (figure 5.2), even there is the small 
breathing variation at the exhale phase between CT simulation and treatment, the 
resultant dose is shown being insignificantly affected.  Similar receiving dose was 
estimated by the DVHs of PTV_ref obtained from dose planning and treatment.   
 
Figure A.3. The upper diagram shows the breathing pattern obtained during CT 
simulation and treatment, the small variation in breathing amplitude was shown at 
the exhaled region. The resultant 4D dose during treatment is estimated by summing 
the TDx weighted with time. The minimum accumulated dose of the PTV_ref during 
dose planning and treatment were estimated using the 4D volume dose histograms 
(lower diagram).   
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